Finex logo
Finex Intelligence

Market Signal Briefing

Wire-ready dashboard awaiting your first source connection.

Last news saved at Mar 30, 13:54 1mo ago Cron last ran Mar 30, 13:54 1mo ago Awaiting first source
Switch language
91,488 Stories ingested Auto-fetched market intel nonstop.
0 Distinct tickers Add sources to start tracking symbols
Trending sources Waiting for fresh intel
Hot tickers Surfacing from current coverage
Details Saved Published Title Source Tickers
2025-11-30 04:06 5mo ago
2025-11-29 22:23 5mo ago
The Deal With Meta: Google's AI Chips To Power A New Cycle Of Growth stocknewsapi
GOOG GOOGL
Analyst’s Disclosure:I/we have a beneficial long position in the shares of GOOGL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
2025-11-30 04:06 5mo ago
2025-11-29 22:25 5mo ago
CPTN DEADLINE ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Cepton, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CPTN stocknewsapi
CPTN
November 29, 2025 10:25 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 29, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers or sellers of common stock of Cepton, Inc. (NASDAQ: CPTN) between July 29, 2024 and January 6, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline.

SO WHAT: If you purchased or sold Cepton common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Cepton class action, go to https://rosenlegal.com/submit-form/?case_id=45981 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements regarding Cepton's business, operations, and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (1) Cepton had received a credible third-party bid valuing Cepton at more than double the Koito Acquisition (Cepton's merger with Koita Manufacturing Co., Ltd.); (2) Cepton's Board of Directors failed to meaningfully explore the foregoing offer and failed to disclose its terms when recommending that Cepton's shareholders approve the Koito Acquisition; (3) consequently, Cepton's shareholders were deprived of the opportunity to meaningfully consider whether to accept or reject the Koito Acquisition; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times.

To join the Cepton class action, go to https://rosenlegal.com/submit-form/?case_id=45981 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276347
2025-11-30 04:06 5mo ago
2025-11-29 22:27 5mo ago
DXCM DEADLINE ALERT: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DXCM stocknewsapi
DXCM
November 29, 2025 10:27 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 29, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead plaintiff deadline.

SO WHAT: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the DexCom class action, go to https://rosenlegal.com/submit-form/?case_id=28133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) DexCom had made material design changes to the G6 and G7 continuous glucose monitoring ("CGM") systems that were unauthorized by the U.S. Food and Drug Administration (the "FDA"); (2) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (3) accordingly, defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (4) Defendants downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; (5) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm; and (6) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the DexCom class action, go to https://rosenlegal.com/submit-form/?case_id=28133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276348
2025-11-30 04:06 5mo ago
2025-11-29 22:30 5mo ago
Best Stock to Buy Right Now: Target vs. Costco stocknewsapi
COST TGT
Costco's shares have pulled back 17% from their highs, but struggling Target's stock still has a more attractive valuation.

Investors need to consider what they're getting when they buy a stock. That includes both the business itself and the price tag that Wall Street is awarding the business.

There's a difficult choice to make today if you're considering Target (TGT +0.91%), a struggling retailer, versus Costco (COST +0.59%), a thriving one.

Which one is the better buy?

Image source: Getty Images.

What does Costco do?
Costco is a club store, which means consumers pay a membership fee for the privilege of shopping at a Costco. Roughly half of the company's operating income is derived from membership fees, which allows the retailer to be aggressive with its prices.

Simply put, Costco can accept lower margins than most retail competitors and, thus, entice its customers to keep coming back with low prices.

Today's Change

(

0.59

%) $

5.33

Current Price

$

913.59

The company's fiscal fourth-quarter 2025 same-store sales were impressive, up 5.7%. Digital sales rose 13.6%. Costco is hitting on all cylinders right now, which makes some sense, since consumers appear to be focused on getting the best prices they can find amid heightened economic uncertainty.

What does Target do?
Target is a more traditional retailer, utilizing a big-box format. It offers a wide selection of products, with a focus on providing customers with a more upscale shopping experience. That includes both product selection and store feel, but it comes with slightly higher prices than some of its competitors. That means Target is currently out of step with value-conscious consumers.

Today's Change

(

0.91

%) $

0.82

Current Price

$

90.62

This fact is clearly evident on the company's income statement. Overall, same-store sales were lower by 2.7%. Digital sales growth was really the lone bright spot, up 2.4%. However, the company's physical stores more than offset that with a 3.8% same-store-sales decline. Consumers are voting with their feet, and Target's premium-tinted experience isn't what they're looking for right now.

What are you getting for your money?
The market has been volatile, and Costco's stock is currently down more than 15% from its 52-week high. That's not great, but the average retail stock, using SPDR S&P Retail ETF (XRT 0.08%) as a proxy, is down around 10%. Target, meanwhile, is down 40% from its 52-week high and nearly 70% from the highs it reached in 2021. Investors are voting with their feet, too, and they've been dumping Target at a rapid clip compared to Costco.

Given the divergent performance of the two businesses, it makes sense that Costco's stock is performing relatively better than Target's. And if you're a growth investor, Costco's still strong business performance will probably be enticing to you. There's just one small problem on the valuation side of the equation.

Costco's price-to-sales, price-to-earnings, and price-to-book value ratios are all above their five-year averages even after the stock's price pullback. It is still on the expensive side. Growth stocks are often expensive to own, but Costco appears particularly pricey right now. Even growth investors will probably want to tread with caution here.

TGT data by YCharts

Target, meanwhile, looks cheap. Its price-to-sales, price-to-earnings (P/E), and price-to-book ratios are all well below their five-year averages. As noted, there's a good reason for the discounted price, but there's a little wrinkle here to consider.

Target is a Dividend King, with more than 50 consecutive years' worth of annual dividend increases. It's been through hard times before and survived them. It seems highly likely that Target will manage to do so again this time around, if history is any guide.

Notably, Target's trailing-12-month dividend payout ratio is fairly reasonable at around 55%. So the dividend doesn't look like it's at a huge risk of being cut right now. More aggressive dividend investors, along with value investors, will probably appreciate the lofty 5.3% yield on offer.

Different investors and different outcomes
Costco is a growth stock, but even after a recent pullback, it's still a historically expensive growth stock. It's probably best left on the wish list for most investors at this time. Target is a value stock working on a business turnaround. The risk is high as the company navigates a period of weakness, but if you can tolerate a bit of uncertainty, the valuation and yield are both attractive.
2025-11-30 04:06 5mo ago
2025-11-29 22:30 5mo ago
MRX DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages Marex Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRX stocknewsapi
MRX
November 29, 2025 10:30 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 29, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Marex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Marex class action, go to https://rosenlegal.com/submit-form/?case_id=43100 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Marex sold over-the-counter financial instruments to itself; (2) Marex had inconsistencies in its financial statements between its subsidiaries and related parties, including as to intercompany receivables and loans; (3) as a result of the foregoing, Marex's financial statements could not be relied upon; and (4) as a result of the foregoing, defendants' positive statements about Marex's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Marex class action, go to https://rosenlegal.com/submit-form/?case_id=43100 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276345
2025-11-30 04:06 5mo ago
2025-11-29 22:38 5mo ago
Montrose Environmental Looks Good Despite Recent Price Drop stocknewsapi
MEG
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
2025-11-30 04:06 5mo ago
2025-11-29 22:42 5mo ago
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INSP stocknewsapi
INSP
November 29, 2025 10:42 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 29, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the "Class Period"), of the important January 5, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Inspire Medical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Inspire Medical class action, go to https://rosenlegal.com/submit-form/?case_id=21452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 5, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants misrepresented and failed to disclose key facts about Inspire V, a sleep apnea device, including the actual market demand for the device and whether Inspire Medical had taken the steps necessary to launch it. Defendants issued a series of materially false and misleading statements that led investors to believe that demand for Inspire V was strong and that Inspire Medical had taken the necessary steps for a successful launch. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Inspire Medical class action, go to https://rosenlegal.com/submit-form/?case_id=21452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276349
2025-11-30 04:06 5mo ago
2025-11-29 22:43 5mo ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Perrigo Company plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - PRGO stocknewsapi
PRGO
November 29, 2025 10:43 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 29, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Perrigo Company plc (NYSE: PRGO) between February 27, 2023 and November 4, 2025, both dates inclusive (the "Class Period"), of the important January 16, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Perrigo securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Perrigo. class action, go to https://rosenlegal.com/submit-form/?case_id=48085 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made materially false and/or misleading statements and or failed to disclose that: (1) the infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance; (2) Perrigo needed to make substantial capital and operational expenditures above Perrigo's outwardly stated cost estimates to remediate the infant formula business; (3) there were significant manufacturing deficiencies in the facility for Perrigo's infant formula business; (4) as a result of the foregoing, Perrigo's financial results, including earnings and cash flow, were overstated; and (5) as a result of the foregoing, defendants' positive statements about Perrigo's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Perrigo class action, go to https://rosenlegal.com/submit-form/?case_id=48085 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276346
2025-11-30 04:06 5mo ago
2025-11-29 22:45 5mo ago
JHX DEADLINE ALERT: ROSEN, A RANKED AND LEADING FIRM, Encourages James Hardie Industries plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - JHX stocknewsapi
JHX
November 29, 2025 10:45 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 29, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of James Hardie Industries plc (NYSE: JHX) between May 20, 2025 through August 18, 2025, both dates inclusive (the "Class Period") of the important December 23, 2025 lead plaintiff deadline.

SO WHAT: If you purchased James Hardie common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the James Hardie class action, go to https://rosenlegal.com/submit-form/?case_id=46976 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 23, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, James Hardie Industries plc misled investors about the strength of its key North America Fiber Cement segment between May 20 and August 18, 2025. Despite knowing by April and early May that distributors were destocking inventory, James Hardie falsely claimed demand remained strong and that stock levels were "normal." When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the James Hardie class action, go to https://rosenlegal.com/submit-form/?case_id=46976 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276350
2025-11-30 04:06 5mo ago
2025-11-29 22:53 5mo ago
Nutex Health: Fairly Valued After Pullback, But Wait For A More Ideal Entry Point (Rating Upgrade) stocknewsapi
NUTX
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
2025-11-30 04:06 5mo ago
2025-11-29 23:00 5mo ago
AGL Investor News: If You Have Suffered Losses in agilon health, inc. (NYSE: AGL) in Excess of $100K, You Are Encouraged to Contact The Rosen Law Firm About Your Rights stocknewsapi
AGL
NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of agilon health, inc. (NYSE: AGL) resulting from allegations that agilon health may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased agilon health securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=46039 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On August 4, 2025, agilon health issued a press release entitled “agilon health Reports Second Quarter 2025 Results.” Commenting on the results, agilon health’s Executive Chair stated that “as we progressed through this transition year, it’s become clear that the industry headwinds are more acute than previously expected[.]” Further, the release announced that the company was “suspending its previously issued full-year 2025 financial guidance and related assumptions.”

On this news, agilon health’s stock fell 51.5% on August 5, 2025.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com
2025-11-30 04:06 5mo ago
2025-11-29 23:05 5mo ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SKYE stocknewsapi
SKYE
November 29, 2025 11:05 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 29, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"), of the important January 16, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Skye Bioscience, Inc. class action, go to https://rosenlegal.com/submit-form/?case_id=48064 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements regarding Skye's business, operations, and prospects. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (1) nimacimab was less effective than defendants had led investors to believe; (2) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Skye Bioscience class action, go to https://rosenlegal.com/submit-form/?case_id=48064 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276296
2025-11-30 03:06 5mo ago
2025-11-29 20:45 5mo ago
What Is the Smartest Quantum Computing Stock to Buy Right Now? stocknewsapi
NVDA
Pure-plays like IonQ, Rigetti Computing, and D-Wave Quantum remain the most popular opportunities in quantum computing at the moment.

For the past three years, investing in artificial intelligence (AI) stocks was reserved almost exclusively for companies designing semiconductors or developing next-generation software.

Over the last year, however, a new pocket of the AI landscape has become increasingly popular. Investors are now complementing their core AI positions with quantum computing stocks. As is the case with any new trend, there are a number of opportunities in the quantum AI market -- some more established than others.

Below, I'll break down why Nvidia (NVDA 1.83%) could be the smartest quantum computing stock to buy right now and detail how the chip giant's approach to this emerging technology differs from the competition.

Image source: Nvidia.

Who are the major players in quantum computing?
The quantum computing market can be split into two categories. On one side are such pure plays as IonQ, Rigetti Computing, and D-Wave Quantum. In addition, cloud hyperscalers like Microsoft, Alphabet, and Amazon have also made investments in quantum computing.

For the most part, the pure plays have garnered limited business traction so far. One reason for that is quantum computing is still an exploratory technology with little in the way of commercial applications.

In addition, all three pure-plays are investing heavily into research and development. They're trying to prove that their trapped ion and quantum superconducting approaches will actually yield a technological breakthrough that leads to widespread adoption at the enterprise level. Until this happens, companies like IonQ, Rigetti, and D-Wave will likely continue burning cash.

In big tech, Alphabet, Amazon, and Microsoft are each designing their own custom quantum computing chips. While such an approach could lead to additional products and services that can be integrated into their broader cloud infrastructures, none of these companies uses quantum AI within their respective ecosystems yet.

Today's Change

(

-1.83

%) $

-3.30

Current Price

$

176.96

How is Nvidia involved with quantum computing?
In order to appreciate Nvidia's role in the quantum computing realm, it's important to first understand how this technology actually works.

In classical computing, developers write code in a series of binary bits -- 0's and 1's. In quantum computing systems, these bits can exist in multiple places at the same time through a property known as superposition. For this reason, the underlying code in quantum architecture is written in qubits (quantum bits) as opposed to a binary structure.

While quantum computers can theoretically process complex simulations at much faster speeds compared to traditional computing systems, qubits themselves are quite fragile and prone to errors.

This is where Nvidia enters the equation. Nvidia sells a full stack of hardware and software tools that can be paired with quantum supercomputers. For instance, the company's GPUs, CPUs, CUDA-Q software platform, and NVQLink interconnect all serve as the infrastructure backbone for a hybrid quantum-classical computing environment.

Nvidia isn't trying to build its own computer or design the best quantum chip. Instead, Nvidia's approach is more agnostic. It's seeking to integrate with different types of quantum systems, all while leveraging its core AI infrastructure stack along with newer quantum-oriented product lines as well.

This playbook is quite savvy, as Nvidia's approach allows the company to continue selling its GPU hardware while simultaneously parlaying its existing infrastructure into a new series of quantum computing services. In essence, Nvidia is taking more of a pick-and-shovel approach to quantum computing -- using this emerging technology to remain an industry leader within the broader AI opportunity.

Image source: Getty Images.

Is Nvidia stock a buy right now?
As of this writing (Nov. 24), Nvidia's forward price-to-earnings (P/E) multiple is 23.4. To put this into perspective, the stock was trading around 34 times forward earnings this time last year. I think this level of multiple compression tells a lot about how the market views Nvidia right now. Just three years ago, the company was seen as the ultimate darling of the AI revolution.

However, with concerns about AI becoming a stock market bubble on the rise, in combination with new competition from Advanced Micro Devices and custom silicon designs from the hyperscalers, some investors may fear that Nvidia's best days are behind it.

Meanwhile, the company continues to innovate at a rapid pace -- introducing new GPU architectures as well as positioning itself for emerging opportunities across robotics, autonomous systems, telecoms, and of course, quantum computing. Each of these efforts is a calculated move to expand Nvidia's long-run total addressable market (TAM).

Against this backdrop, I think Nvidia stock is becoming too cheap to ignore. In my eyes, the market is heavily discounting the company's next wave of growth -- making Nvidia a compelling opportunity to buy and hold as sentiment eventually catches up with the underlying fundamentals of a company that continues to execute at a record pace.
2025-11-30 03:06 5mo ago
2025-11-29 20:51 5mo ago
Is Netflix Stock a Buy With a Fresh Stock Split Behind It? stocknewsapi
NFLX
Netflix's 10-for-1 stock split comes at a time of incredible growth at the company. Time to buy?

Netflix (NFLX +1.35%) just completed a 10-for-1 stock split, moving its share price back near the hundred-dollar level while leaving the company's market value unchanged.

The split comes at a time of significant momentum for the underlying business. The streaming leader's revenue has been growing rapidly, and management expects its operating margin to expand this year -- even as Netflix spends heavily on new series and films and pushes into advertising technology and live events.

With a fresh split behind it and growth still healthy, the key question for investors is whether the current price already reflects the company's prospects, given a valuation that remains demanding.

Image source: Netflix.

Netflix is firing on all cylinders
In the second quarter of 2025, Netflix grew revenue 16% year over year, followed by 17% growth in the third quarter as paid memberships and pricing both increased -- and a small but fast-growing advertising business helped results.

Netflix's profitability has also remained robust, despite some noise. Operating margin in the third quarter landed at 28%, down from 34% in the second quarter and 30% in the third quarter of 2024 because of a Brazilian tax charge that management views as a one-off item. But Netflix notably said it would have exceeded its operating income forecast without that charge.

What's impressive is that Netflix's full-year outlook for operating margin still calls for expansion -- even with this massive cost built into the guidance. Specifically, management guided for a full-year operating margin of 28%, up from 27% last year.

Then there's the company's three-year-old advertising business. It's crushing it.

"We recorded our best ad sales quarter ever. We are now on track to more than double ad revenue this year," co-CEO Gregory Peters said.

Looking ahead
Netflix is finishing 2025 with a heavy slate that includes the final season of Stranger Things, alongside new seasons of other popular series, which should support viewing hours and make the platform more attractive to both subscribers and advertisers, ultimately helping the company finish the year strong.

Combining its recent revenue momentum with its small but fast-growing advertising business, management is optimistic about the future. Management said it expects revenue to once again grow about 17% year over year in Q4.

Impressively, Netflix expects to generate total free cash flow for the full year of 2025 of about $9 billion, even as it continues to invest in content, advertising technology, and a growing slate of live events.

Netflix's valuation after the split
Stock splits, of course, do not change intrinsic value. And Netflix's 10-for-1 split is no exception. The split increased the number of shares while reducing the price of each one, leaving the company's roughly $450 billion market capitalization intact -- and the post-split price a little above $100 per share.

Today's Change

(

1.35

%) $

1.43

Current Price

$

107.57

But are shares attractive?

Netflix trades at about 44 times earnings and about 10 times sales, levels that sit well above many other large media and entertainment businesses. Of course, those multiples look more understandable once investors consider Netflix's rapid revenue growth rate and substantial operating margin. Yet, they also mean the market is counting on strong execution from the core business, as well as Netflix's ad tier and other growth initiatives like its live programming and games.

Traditional rivals such as Walt Disney and Comcast trade at much lower valuations. But they don't boast the same attractive growth profile -- and their streaming operations remain far less profitable than Netflix's globally scaled service. This helps explain why investors are willing to pay a significant premium for Netflix stock.

Overall, Netflix looks like a strong business at a demanding price -- a well-deserved demanding price. For that reason, I think shares look moderately attractive. But any new position in the stock should be small, as the stock's premium price means shares have valuation risk in a competitive market that includes streaming services from both traditional rivals and deep-pocketed technology giants.
2025-11-30 03:06 5mo ago
2025-11-29 21:05 5mo ago
The List of Analysts Who Think Tesla Will Benefit Immensely From Robotaxis Keeps Growing stocknewsapi
TSLA
Some analysts are bullish on Tesla's self-driving vehicles gamble, but investors should take a wait-and-see approach.

While many automotive companies are trying to figure out how to transition to electric vehicles (EVs), Tesla (TSLA +0.82%) is in the midst of figuring out how to pivot to robotics and autonomous vehicles (AVs). CEO Elon Musk has made this shift a priority, and even part of his potential $1 trillion pay package rests on whether he delivers on some AV goals.

There is no guarantee Tesla can pull it off. Investments in AVs are expensive, and Tesla has significant competition from Alphabet's Waymo and others.

However, an increasing number of analysts believe Tesla is on the right track, including Stifel analyst Stephen Gengaro, who recently said that Tesla stock could rise 25% if it achieves its AV goals. With more analysts getting bullish on Tesla's self-driving ambitions, it's worth taking a look at what these analysts are expecting and what challenges Tesla faces.

Image source: Tesla.

These analysts think robotaxis will be huge for Tesla
Gengaro said in a recent investor note that Tesla's full self-driving (supervised) system and robotaxi services "are critical to the story" for the company and a large part of his valuation of the company's share price -- leading to the estimate that Tesla's stock could get a 25% bump from the tech.

The optimism stems from Tesla's opportunity to use its artificial intelligence technology to improve its semi-autonomous systems and for its nascent robotaxi service to continue expanding. Other analysts believe AVs could be a major catalyst for the company as well. Here are a few of them:

Cathie Wood of Ark Invest estimates that 90% of Tesla's enterprise value and earnings could come from its autonomous systems by 2029.
Wedbush's Dan Ives thinks Tesla's market cap could reach $2 trillion by the end of next year because of its autonomous vehicle pursuits.
Cantor Fitzgerald's Andres Sheppard believes Tesla is on track with its autonomous Cybercab production for 2026 and boosted Tesla's share price target last month from $355 to $510 as a result.
Gene Munster of Deepwater Asset Management forecasts that up to 40% of Tesla's operating income could come from robotaxis and licensing FSD by 2030.

Some autonomous vehicle estimates help support the case for Tesla's long-term AV opportunity. Specifically, autonomous vehicles and services are projected to be worth $1.4 trillion by 2040.

Today's Change

(

0.82

%) $

3.51

Current Price

$

430.09

Why investors shouldn't get overly excited just yet
Tesla has said that it will launch its robotaxi service in five new cities and have 1,500 self-driving cars in service by the end of this year. Currently, Tesla offers limited service in Austin, Texas. The company also plans to build its Cybercab vehicles for its robotaxi service, which will be produced sans steering wheel and pedals, beginning in April.

But Tesla's pivot to AVs comes at a time when it's not performing well financially.

Consider that Tesla's profits are falling, with generally accepted accounting principles (GAAP) net income declining 37% in the third quarter to $1.4 billion. At the same time, the company's operating expenses jumped by 50% to $3.4 billion.

The problem is that Tesla will have to spend billions of dollars to build its Cybercabs and invest in AV technologies. But it's facing financial hurdles as EV tax credits have expired, and as car buyers shift their attention away from EVs and toward hybrids.

This doesn't mean Tesla's autonomous vehicle ambitions are doomed, of course. The company certainly has disproved naysayers plenty of times before. However, investors buying Tesla stock now, hoping to ride to AV glory, should understand that Tesla is pivoting to costly autonomous vehicle technology at a challenging time in the EV industry and a financially difficult period in Tesla's history.

All of which means that investors should probably wait to see how some of this plays out before jumping on board with Tesla just yet.
2025-11-30 03:06 5mo ago
2025-11-29 21:05 5mo ago
Volaris Completed EASA-Mandated A320 Inspections and Repairs with No Cancellations and Minimal Delays stocknewsapi
VLRS
MEXICO CITY, Nov. 29, 2025 (GLOBE NEWSWIRE) --  Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS and BMV: VOLAR) (“Volaris” or “the Company”), the ultra-low-cost carrier (ULCC) serving Mexico, the United States, Central and South America, announed today the successful completion of all inspections and repairs required under the Airworthiness directive issued last Friday by the European Union Aviation Safety Agency (EASA) on the official notification from Airbus (AOT Alert Operators Transmission) affecting approximately 6,000 A320-family aircraft worldwide. The directive addressed a flight-control software issue potentially influenced by solar flares, and in some cases required associated hardware checks.

Volaris completed the full scope of work across its fleet without a single flight cancellation and with only minimal delays, ensuring passengers remained largely unaffected throughout the process.

Enrique Beltranena, Volaris’ President and CEO, said: “Our technical and operational teams responded with exceptional speed and discipline. Their seamless coordination with Airbus and authorities allowed us to maintain our full schedule while ensuring the highest standards of safety and reliability.”

Key points:

All required software updates and hardware verifications have been finalized.No major impact to passenger itineraries, with zero cancellations.Only minor delays were recorded as aircraft returned to service.No material financial impact is expected.
Volaris reaffirmed its commitment to operational excellence, safety leadership and proactive fleet management, noting that the incident underscores the airline’s ability to respond swiftly to manufacturer and regulatory mandates while protecting the customer experience.

Investor Relations Contact
Liliana Juárez / [email protected]

Media Contact
Ricardo Flores / [email protected] 

About Volaris
*Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (“Volaris” or “the Company”) (NYSE: VLRS and BMV: VOLAR) is an ultra-low-cost carrier, with point-to-point operations, serving Mexico, the United States, Central, and South America. Volaris offers low base fares to build its market, providing quality service and extensive customer choice. Since the beginning of operations in March 2006, Volaris has increased its routes from 5 to more than 221 and its fleet from 4 to 154 aircraft. Volaris offers around 500 daily flight segments on routes that connect 44 cities in Mexico and 30 cities in the United States, Central, and South America, with one of the youngest fleets in Mexico. Volaris targets passengers who are visiting friends and relatives, cost-conscious business and leisure travelers in Mexico, the United States, Central, and South America. For more information, please visit ir.volaris.com. Volaris routinely posts information that may be important to investors on its investor relations website. The Company encourages investors and potential investors to consult the Volaris website regularly for important information about Volaris.
2025-11-30 03:06 5mo ago
2025-11-29 21:07 5mo ago
Could the Nvidia Killer Be Hiding in Plain Sight? 3 Stocks to Watch stocknewsapi
AMZN GOOG GOOGL MSFT
Nvidia was an early leader in AI and has reaped the rewards. But it may soon need to defend its crown.

The artificial intelligence (AI) market is booming, and could grow from $235 billion last year to $631 billion by 2028. The top AI stocks have already enjoyed tremendous returns since early 2023, and the future looks bright. Remember, the internet hasn't stopped growing since its initial boom decades ago.

Nvidia has arguably been the most apparent AI winner thus far. Its GPU chips have become the de facto choice for AI hyperscalers training and operating AI models, a Golden Goose that has generated $187 billion in revenue over the past four quarters alone.

But most of that has come from a relatively small handful of these hypercalers. As spending for all these data center projects adds up, the pressure is building for hyperscalers to cut costs.

These three companies, which are, ironically, Nvidia's own customers, could kill Nvidia's Golden Goose. They are threats sitting in plain sight.

Image source: Getty Images.

1. Alphabet
After the recent unveiling of its Gemini 3 AI model, Alphabet (GOOGL +0.06%)(GOOG 0.05%) might pose the most serious threat to Nvidia's AI dominance. From most accounts, Gemini 3 is a highly impressive step forward for AI models. But perhaps the most remarkable thing about Gemini 3 is that Alphabet apparently trained it on its own proprietary AI chips rather than Nvidia's GPUs.

Today's Change

(

0.06

%) $

0.19

Current Price

$

320.14

Nvidia's GPUs use the company's CUDA programming to efficiently harness the immense computing power of GPUs for AI tasks. However, Alphabet's Tensor Processing Units (TPUs) are application-specific integrated circuits (ASICs), meaning they are designed and built for one job and one job only. In this case, that's Alphabet's AI.

Alphabet's success in training Gemini 3 with its TPUs shows that Nvidia's GPUs aren't irreplaceable. That doesn't mean other companies will easily do what Alphabet did, but it does send the message that it's possible. Over time, other hyperscalers could design their own AI ASICs, potentially eating into Nvidia's business.

2. Amazon
Other hyperscalers have also developed custom AI chips. Amazon (AMZN +1.77%) operates AWS, the world's leading cloud computing services platform. AI has created tailwinds for AWS because it primarily runs in the cloud, as does most modern software. Amazon continues to build data centers to increase its cloud capacity, and those data centers require many chips.

Today's Change

(

1.77

%) $

4.06

Current Price

$

233.22

Amazon has developed its own AI chip, Trainium, and has begun to assert it more. The company has a partnership with Anthropic, the developer of the AI application Claude. The two companies recently announced the activation of Project Rainier, a massive AI chip cluster. It's using nearly half a million Trainium2 chips, and that will scale to over 1 million by the end of this year.

It doesn't necessarily mean Nvidia is out of the picture, but it loosens Nvidia's stranglehold on the market. At the very least, Nvidia, which has enjoyed 70% gross margins over the past year, could begin feeling some pressure. Between Amazon's own chip needs and those of a prominent AI developer such as Anthropic, further leaning into Trainium is another potential headwind for Nvidia's growth.

3. Microsoft
If you've noticed a theme by now, you'd be correct. Some of Nvidia's biggest customers have begun looking for ways to reduce their dependence on Nvidia's GPUs. Microsoft (MSFT +1.34%) is yet another name on this list for similar reasons. Not only is Microsoft's Azure the world's second-leading cloud services platform, but it also has a close partnership with ChatGPT developer OpenAI.

Today's Change

(

1.34

%) $

6.52

Current Price

$

492.02

OpenAI is the leading AI developer, as ChatGPT is the most popular AI app. However, the company is operating at heavy losses and has recently faced intensifying scrutiny over how it will fund $1.4 trillion in AI infrastructure it has signed agreements for. It seems that the days of writing blank checks for GPUs are nearly over.

Microsoft and OpenAI recently restructured their partnership and will work more closely on custom AI chips. OpenAI has been designing custom chips with Broadcom, and Microsoft CEO Satya Nadella recently suggested that Microsoft will contribute to those efforts so that both companies can benefit. Once again, it's a shot across Nvidia's bow, a signal that its lucrative dominance in AI data center chips may soon face serious challenges.
2025-11-30 03:06 5mo ago
2025-11-29 21:38 5mo ago
3 Things Lululemon Must Fix Before the Stock Can Recover stocknewsapi
LULU
Lululemon isn't broken, but the brand has clearly hit a tougher chapter.

Lululemon Athletica (LULU +1.24%) spent years as one of the most consistent growth stories in retail. The company built a premium brand, expanded into new categories, and delivered industry-leading margins. Investors rarely questioned its ability to drive higher sales and steady earnings growth.

But the last few quarters shifted that narrative. U.S. demand softened, product execution looked uneven, and competition intensified. As a result, the stock now trades at one of its lowest valuations in years.

For long-term investors, this moment raises a simple question: What needs to change before Lululemon gets its momentum back? Based on recent results and management commentary, three priorities stand out.

Image source: Getty Images.

Lululemon needs to rebuild product discipline
Product execution has always been the heart of Lululemon's identity. The company differentiated itself with clean designs, performance fabrics, and a consistent aesthetic that appealed to both fitness and lifestyle shoppers. Recently, that consistency slipped.

A widely discussed Jefferies report highlighted several concerns, including brighter color palettes and heavier logo placement. These aren't fatal issues, but they suggest that the company steered too far from its proven merchandising strategy.

Rebuilding product discipline involves more than revisiting a few colorways. Lululemon needs to tighten its assortment, refocus on core categories, and ensure that new designs add meaningful differentiation instead of noise.

The good news: Lululemon management acknowledges the issue and has already begun to respond. On its recent earnings call, the company committed to increasing the share of new styles in its assortments from 23% to 35% and shortening its design-to-market lead times. That reset effort aims to reignite demand, although its full effect remains to be seen.

Today's Change

(

1.24

%) $

2.25

Current Price

$

184.19

It must stabilize U.S. demand and store traffic
The second issue sits squarely in the U.S. market. Lululemon reported 3% revenue decline on a constant currency basis in the latest quarter, thanks to softer traffic, weaker demand for some staple categories, and more price sensitivity among shoppers. For a brand that historically shrugged off economic swings, these trends matter.

Lululemon doesn't need explosive U.S. growth to win long-term. It does, however, need stabilization. Investors want to see that the slowdown reflects temporary softness, rather than a fundamental shift in how people view the brand. That means improving category performance, increasing store engagement, and ensuring that marketing and product messaging reconnect with the core customer.

Store execution will matter as well. Lululemon's retail locations have long been central to its community identity, from in-store events to influencer partnerships. Re-energizing those touchpoints could help rebuild momentum without heavy discounting or margin-diluting promotions.

If traffic stabilizes, even modestly, it will signal that the U.S. slowdown is cyclical rather than structural. That distinction is critical for investor confidence.

Lululemon must restore margin momentum amid tariff and cost pressure
The third priority involves margins. Lululemon maintained some of the highest gross margins in apparel for years thanks to premium pricing, strong sell-through, and a tight supply chain. But new tariff rules and higher import costs created pressure. The effect is already eating into margin, with the latest quarter's gross margin falling by 1.1% amid higher markdowns, tariffs, and other costs.

Margin compression doesn't break the thesis, but it does limit earnings growth in the short term. To fix this, the company needs to manage inventory more tightly, improve sourcing efficiency, and maintain pricing strength without alienating customers. Lululemon still has room to optimize its cost structure, and the direct-to-consumer model remains a significant advantage. The question is how quickly the company can offset these new pressures.

Investors should watch gross margin trends closely. Even small improvements will indicate that the company is navigating tariff changes effectively and preserving the profitability that made its business model so attractive.

What does it mean for investors?
Lululemon's challenges are real, but none of them signal a broken business. International markets continue to grow quickly. The balance sheet remains strong. Customer loyalty remains high. And the global athleisure market still offers a long runway.

The stock's recent pullback reflects a shift in expectations, not a collapse in fundamentals. If Lululemon tightens its product direction, stabilizes U.S. performance, and restores margin discipline, the company can reestablish the steady growth profile that powered its earlier success.

The next few quarters will show whether Lululemon can execute with the consistency investors have come to expect.
2025-11-30 03:06 5mo ago
2025-11-29 21:51 5mo ago
Airlife Gases Acquires Control of Royal Helium Ltd. stocknewsapi
RHCCF
November 29, 2025 21:51 ET

 | Source:

Airlife Gases Private Limited

PUNE, India, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Airlife Gases Private Limited (“AirLife”) is pleased to announce that it has completed the acquisition, through a wholly-owned subsidiary, of a total of 79,901,328 Class A common voting shares (the “Common Shares”) of Royal Helium Ltd. (“Royal Helium”) and 4,000,000 share purchase warrants of Royal Helium (“Warrants”), representing approximately 52.9% of the issued and outstanding Common Shares on a fully-diluted basis. Each Warrant can be exercised to purchase one Common Share at a price of $0.65 per share for a period of 36 months.

Royal Helium is an exploration, production and infrastructure company with a primary focus on the development of helium and associated gases. Royal Helium’s extensive footprint includes prospective helium permits and leases across Southern Saskatchewan and southeastern Alberta, Canada.

Royal Helium’s reservoirs are carried primarily with nitrogen. Nitrogen is not considered a greenhouse gas (GHG) and therefore has a low GHG footprint when compared to other jurisdictions that rely on large scale natural gas production for helium extraction. Helium extracted from wells in Saskatchewan and Alberta can be up to 90% less carbon intensive than helium extraction processes in other jurisdictions.

AirLife has entered into an investor rights agreement with Royal Helium pursuant to which AirLife has the right to nominate such number of directors of Royal Helium to have majority board representation, and one of such nominee directors shall be the chair of the board of directors. AirLife has also been granted the corporate naming rights of Royal Helium, subject to regulatory and shareholder approval.

In addition, AirLife has been granted the exclusive right to enter into a helium and specialty gases offtake agreement with respect to all helium and all other products produced by Royal Helium’s subsidiaries.

Syndicate Lending Corporation acted as the sole agent to AirLife on this transaction.

________________________________________

About AirLife Gases Private Limited

AirLife Gases Private Limited is a multi-national supplier of helium and specialty gases, serving high-growth sectors such as healthcare, fiber optics, semiconductors, and aerospace & defense. Operating from multiple international facilities and supported by a robust global distribution network, AirLife has built long-standing supply relationships with industrial clients and helium producers, underpinned by rigorous quality assurance and regulatory compliance.

“This transaction marks a significant milestone for AirLife as we evolve into an integrated helium producer,” said Kiran Karnawat, Chairman & CEO of AirLife Gases Private Limited. “Through this strategic deal, we are expanding our footprint in Canada’s helium corridor, securing direct access to upstream production, and contributing to job creation and industrial growth in Alberta and Saskatchewan. The combination of AirLife’s global distribution expertise with Royal Helium’s proven assets will enhance supply reliability and deliver long-term value to customers worldwide.”

With the closing of the transaction, AirLife is strategically evolving from a global distributor to an integrated helium producer, expanding its role across the value chain. This transition will enable AirLife to participate directly in upstream helium production while leveraging its extensive logistics and customer infrastructure to deliver end-to-end supply solutions. By aligning production with established distribution capabilities, AirLife aims to strengthen supply security for its global customers, reduce reliance on third-party producers, and enhance value creation through vertical integration.

This transaction represents a pivotal milestone in AirLife’s growth strategy—positioning the company as a fully integrated helium enterprise with control over sourcing, production, and global delivery, ensuring sustainable growth in an increasingly supply-constrained market.

________________________________________

About Syndicate Lending Corporation

Syndicate Lending Corporation (SLC) is a financial advisory and strategic debt provider specializing in capital structuring, transaction execution, and cross-border deal facilitation across diverse markets. SLC partners with corporate clients to originate, structure, and complete complex financings and strategic combinations, acting as an advisor, arranger, and exclusive representative where required.

________________________________________

For further information, please contact:

Inam Qureshi, CEO

Syndicate Lending Corporation (Exclusive representative of AirLife Gases Private Limited)

+1 604-829-7007

 [email protected]
2025-11-30 03:06 5mo ago
2025-11-29 21:55 5mo ago
DIVB: A Solid And Cheap Core Dividend ETF, But I Prefer FDVV stocknewsapi
DIVB
SummarySince its strategy change in December 2022, DIVB has delivered above-average dividends and total returns compared to competing large-cap value ETFs. It's also cheap, with an ER of just 0.05%.Its 2.85% estimated dividend yield is solid but certainly not in "high yield" territory, yet that's not what "core" dividend ETFs like DIVB attempt. Instead, it's all about balance.After covering DIVB's selection process, I'll highlight other dividend ETFs with above-average yields and total returns and compare their current fundamentals alongside DIVB's.Overall, I found DIVB's key strengths were on cost, diversification, and value, while it lags behind on growth and quality. Fundamentally, I found FDVV a better all-around pick.DIVB earns a neutral "hold" rating, but I encourage readers to seek out alternatives. Suphachai Panyacharoen/iStock via Getty Images

Investment Thesis I last reviewed the iShares Core Dividend ETF (DIVB) on February 26, 2025, when I rated it a "hold" due to its solid diversification, value, and dividend yield features, but otherwise unappealing factor mix. Since that article was

Analyst’s Disclosure:I/we have a beneficial long position in the shares of FDVV, IVV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You
2025-11-30 03:06 5mo ago
2025-11-29 21:56 5mo ago
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages CarMax, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - KMX stocknewsapi
KMX
November 29, 2025 9:56 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 29, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CarMax, Inc. (NYSE: KMX) between June 20, 2025 and November 5, 2025, both dates inclusive (the "Class Period") of the important January 2, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased CarMax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the CarMax class action, go to https://rosenlegal.com/submit-form/?case_id=47077 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 2, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner 90Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendants recklessly overstated CarMax's growth prospects when, in reality, its earlier growth in the 2026 fiscal year was a temporary benefit from customers buying cars due to speculation regarding tariffs; and (2) as a result, defendants' statements about CarMax's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the CarMax class action, go to https://rosenlegal.com/submit-form/?case_id=47077 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275950
2025-11-30 02:06 5mo ago
2025-11-29 18:10 5mo ago
Trump Floats 50-Year Mortgages: Here's What This Means for Real Estate and Banking Stocks stocknewsapi
AGNC BAC C NLY
If you are looking for a home, a lower monthly payment might sound nice, but the real beneficiary of a longer loan term is going to be the lender.

Buying a home is part of the American dream, but it is also one of the most expensive and challenging aspects of that dream. Making it possible for more people to buy homes is a frequent presidential goal, and Donald Trump is no exception in this regard.

But is the 50-year mortgage a good idea? It depends on whether you are the borrower or the lender. Here's what you need to know.

It usually comes down to a mortgage
Houses are expensive, and most people need to borrow money to afford to buy a home. The loan that they typically use is called a mortgage. The key feature of a mortgage is that it is a self-amortizing loan. That sounds fancy, but it just means that each monthly payment includes an interest payment and a payment toward the principal of the loan.

Image source: Getty Images.

Essentially, you are paying down the loan as you go along so that, when the mortgage is paid off at the end of the loan period, there is nothing left to pay. Some investors view this as a form of forced savings, as each mortgage payment helps build equity in your home.

That said, there's an interesting twist here. Early in the loan, when the principal is largest, the vast majority of the monthly payment goes toward interest. Over time, as the principal is slowly paid down, interest expenses make up an increasingly smaller portion of the monthly payment. This is vital to understand when examining the benefits of taking out a typical 30-year mortgage versus the proposed 50-year mortgage.

If you bought a $450,000 home with a 30-year mortgage and a 6.25% interest rate, your monthly payment would be $2,771. A 50-year mortgage at the same rate would lower the monthly payment to $2,452, according to a CNN analysis.

That's a notable drop, but there's a hidden cost to those savings. Because of the self-amortizing nature of mortgage loans, you are paying more in interest over the life of the loan when you extend the maturity by 20 years. The total amount you'd pay your mortgage lender in interest would be roughly $547,000 with the 30-year loan and a huge $1.02 million with a 50-year loan. So the 50-year loan would cost the homebuyer nearly twice as much in interest.

Mortgage lenders would be the big winners
Pretty clearly, the real winner here is the mortgage lender. To be fair, there is more risk in providing a 50-year loan, as there's more time for unfavorable events to occur. However, given the financial benefits, even the largest banks would likely jump at the chance to offer customers 50-year mortgage loans.

Today's Change

(

1.25

%) $

0.66

Current Price

$

53.65

The largest banks, like Bank of America (BAC +1.25%) or Citigroup (C +1.07%), would be best positioned to benefit. That's because they have the scale to spread their risk across more homebuyers. Their size and brand recognition alone would enable Bank of America and Citigroup to attract sufficient customers to initiate many mortgage loans across a broad geographic footprint. The inherent diversification this provides would likely offset the heightened risk they would face from the increased loan length.

However, there's another type of finance stock that may be even more attractive if the 50-year mortgage loan becomes a reality. Mortgage real estate investment trusts (mREITs), such as Annaly Capital (NLY +0.57%) and AGNC Investment (AGNC +0.48%), purchase mortgages that have been pooled together into bond-like securities. Mortgage REITs make the difference between their costs and the interest they earn on the mortgage securities they buy.

Today's Change

(

0.48

%) $

0.05

Current Price

$

10.49

Investors like mREITs because of their huge dividend yields. Annaly's yield is currently around 12.7%, while AGNC's yield is nearly 14%.

There's a wrinkle, however, since self-amortizing loans mean that a portion of the interest an mREIT earns is principal. In essence, as these REITs pay out dividends, they are returning a portion of an investor's capital. Over time, the value of most mREITs' portfolios tends to decline.

To put a number on that, AGNC's tangible net book value was $17.66 at the start of 2020. Tangible net book value is similar to net asset value for a mutual fund, which is basically the value of the mutual fund's portfolio. Mortgage REITs report this figure quarterly, and it effectively represents the value of their business. At the end of the third quarter of 2025, AGNC's tangible net book value had fallen to $8.28.

Today's Change

(

0.57

%) $

0.13

Current Price

$

22.80

Interest payments would make up a larger portion of an mREIT's income stream if the mortgage securities they bought were backed by 50-year mortgages. So the return of capital in the dividend would be less impactful on the value of the mREIT's business. Thus, the tangible net book value would hold up better over time.

Simply put, longer mortgages would make mREITs more attractive investments because they extend the period over which interest is paid, slowing down the impact of self-amortization.

Good for some, bad for others
It is far from clear if a 50-year mortgage will become a thing. They have been discussed for years as a way to make buying a home easier. However, upon examining the math, the real beneficiaries are likely to be banks and investors who buy mortgage securities. Still, if the 50-year mortgage does gain traction, it could be a change that makes mREITs a more attractive investment for long-term dividend investors.
2025-11-30 02:06 5mo ago
2025-11-29 19:45 5mo ago
Michael Burry Thinks AI Companies Are Overestimating the Useful Life of Chips. Here's Why That Could Be a Big Problem stocknewsapi
NVDA
If depreciation expenses are lower than they should be, earnings numbers could be inflated.

Artificial intelligence (AI) has been a tremendous growth opportunity for tech companies in recent years. It's led to them investing heavily in data centers, chips, and other crucial infrastructure to ensure they don't fall behind their rivals. While it's still debatable just how much of a payoff there will be from all these investments, it has led to surging valuations for many top tech companies.

But one person who is a bit skeptical on the hype in AI is Michael Burry, hedge fund manager and founder of Scion Capital. He's known for predicting the housing crash in 2008. Now, he's turned his attention to AI, where he believes that companies are overestimating the useful life of chips. While that may not seem like a big deal, it could mean that companies are underestimating their expenses, and that could be a big problem for investors.

Image source: Getty Images.

A longer useful life means lower depreciation costs
Estimating the useful life of an asset is crucial in accounting because that's how long of a period a company will be spreading its cost over. The longer the useful life, the lower cost per year. There can be an incentive there for companies to overestimate useful life for the sake of lowering expenses and boosting profits. Investors might scoff at depreciation expenses since they are further down the income statement and they aren't directly related to a company's current day-to-day operating activities, but they can have a material impact on earnings.

If earnings are overstated that means the valuations of these already expensive stocks are even higher than they appear to be. Chipmaker Nvidia (NVDA 1.83%), the most valuable company in the world, trades at 45 times its trailing earnings, which may seem a bit high. But its forward price-to-earnings multiple, which is based on analyst expectations, is relatively modest at 23. That's only slightly higher than the S&P 500 average of 21. It's a chip supplier, and its sales numbers suggest that demand remains robust, which may indeed suggest frequent refresh cycles.

In Nvidia's most recent earnings, the company reported $57 billion in sales for the period ending Oct. 26, which was a year-over-year increase of 62%. CEO Jensen Huang says that "Blackwell sales are off the charts, and cloud GPUs are sold out."

Companies may need to upgrade sooner than investors expect
If Burry's claims are true, then it may not be too long before a troubling pattern, which is a frequent upgrade cycle. If chips are only useful for two to three years, as Burry suggests they might be (versus the five-plus years that hyperscalers are claiming), then that could mean more frequent refresh cycles. Companies may be ramping up capital expenditures every couple of years to stay relevant in what's proving to be an intense AI race.

While this might be good news for Nvidia as it could suggest continually high investments into its chips, it could also put pressure on hyperscalers to pull back on some spending, especially if AI projects aren't paying off but investments remain high.

I believe it's a plausible scenario that chips may be useful for only a few years and that lifespan estimates may be a bit high. With companies rushing out to get ahead of one another, it seems unlikely that a hyperscaler is going to be willing to sit on five- or six-year-old chips. The AI boom could put pressure on hyperscalers to invest more heavily in chips and AI infrastructure on a more frequent basis than investors expect.

Today's Change

(

-1.83

%) $

-3.30

Current Price

$

176.96

Should you be worried about an AI bubble?
If Burry's prediction turns out to be true and companies are setting longer useful lives for AI infrastructure that's unrealistic, then it could indeed be problematic for the tech sector. There's already growing concern that businesses are investing too heavily in AI. If those costs prove to be even higher, then that will only exacerbate those worries.

A bubble may have already formed, and stocks with inflated valuations may be among the most vulnerable to a correction in the near future. With Nvidia trading at a fairly reasonable multiple, it may not be in as bad a shape as other businesses. But the problem is that if there's any sign of softness in AI-related demand, all stocks related to the hype could be due for significant declines, including Nvidia.

Now may be a good time to consider your overall exposure to AI stocks and your risk tolerance. If you're investing for the long haul and still have many investing years to go, then sticking with a blue-chip stock like Nvidia can remain a good move. But if you want to reduce some of your exposure to tech, you may want to consider moving some of your money into exchange-traded funds or indexes that track the S&P 500.
2025-11-30 02:06 5mo ago
2025-11-29 19:47 5mo ago
3 Growth ETFs to Buy With $5,000 and Hold Forever stocknewsapi
QQQ SCHG VUG
If you don't want to invest in individual growth stocks, these ETFs could be worth a second look.

Growth exchange-traded funds (ETFs) broadly focus on companies that are expected to grow their earnings and revenue at an above-average rate compared to the overall market. This can provide long-term investors the potential for significant capital appreciation over the long term, but it's always important to be selective about where you put your money to work.

By holding a basket of numerous growth stocks across various sectors (such as technology, healthcare, and consumer stocks), investing in growth ETFs can allow you to spread risk more effectively than investing in a single stock or a few individual growth stocks. These ETFs also offer you as the investor a streamlined way to invest in companies at the forefront of innovation and emerging trends without needing to perform extensive research and analysis on individual companies.

On that note, if you have $5,000 to invest, here are three top growth ETFs to consider putting some or all of that amount into the next time you go stock shopping.

Image source: Getty Images.

1. Vanguard Growth ETF
Vanguard Growth ETF (VUG +0.50%) is an ETF that tracks the CRSP US Large Cap Growth Index and focuses on large U.S. companies, primarily in technology and consumer cyclical businesses. The fund has an extremely low expense ratio of 0.04%.

The ETF has generated strong average annual returns of approximately 17.4% over the past 10 years. If those returns were to continue in the next decade, this means that a $5,000 investment in the Vanguard Growth ETF could grow to more than $24,000 by the end of that forecast period.

Today's Change

(

0.50

%) $

2.46

Current Price

$

490.84

The ETF holds 160 stocks, with the largest holdings, including megacap companies like Apple, Microsoft, and Nvidia. Other holdings include Eli Lilly, Mastercard, Oracle, and Uber.

For investors who want exposure to large-cap growth companies with high sales and earnings growth potential without investing in individual stocks, the Vanguard Growth ETF could be well worth considering.

2. Invesco QQQ Trust
Invesco QQQ Trust (QQQ +0.80%) tracks the Nasdaq-100 index, which includes the 100 largest nonfinancial companies on the Nasdaq exchange. The ETF is heavily weighted toward the technology sector, but it also includes stocks in the consumer discretionary and healthcare sectors, which could be of interest to investors seeking additional diversification. Its expense ratio is 0.20%.

The ETF also provides investors exposure to companies at the forefront of long-term trends like artificial intelligence (AI), cloud computing, and robotics. Top holdings of the Invesco QQQ Trust include Nvidia, Apple, Microsoft, Broadcom, Amazon, Alphabet, and Tesla. However, you'll also find companies like Costco, Netflix, Intuitive Surgical, and PepsiCo among its various holdings.

Today's Change

(

0.80

%) $

4.89

Current Price

$

619.16

Over the last decade, the Invesco QQQ Trust has outperformed the S&P 500 (^GSPC +0.54%) by a significant margin, with total returns of around 456% for the former versus approximately 276% for the latter. If you break that down to an annualized return over the last 10 years, the Invesco QQQ Trust has delivered 19.6% compared to the market's 14.6%. Were that track record to continue, a $5,000 investment in QQQ now could be worth more than $29,000 in a decade.

3. Schwab U.S. Large-Cap Growth ETF
Schwab U.S. Large-Cap Growth ETF (SCHG +0.52%) boasts a low expense ratio (0.04%) and tracks the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund is concentrated in megacap stocks. Its top holdings, including Nvidia, Microsoft, Apple, Amazon, and Broadcom, account for around half of the ETF's total assets.

NYSEMKT: SCHGSchwab Strategic Trust - Schwab U.s. Large-Cap Growth ETF

Today's Change

(

0.52

%) $

0.17

Current Price

$

32.80

However, if you invest in this ETF you'll also get exposure to other companies, including names like Walt Disney, GE Vernova, and Booking Holdings. The ETF currently holds 197 stocks.

The Schwab U.S. Large-Cap Growth ETF boasts a 10-year annualized return of 18.18% based on its market price at the time of this writing. So, a $5,000 investment in this ETF with a hypothetical annualized performance of 18.18% over a decade -- assuming annual compounding and no additional contributions or withdrawals -- would be worth more than $26,000 at the end of that period.

Rachel Warren has positions in Alphabet, Amazon, and Apple. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Booking Holdings, Costco Wholesale, Intuitive Surgical, Mastercard, Microsoft, Netflix, Nvidia, Oracle, Tesla, Uber Technologies, Vanguard Index Funds - Vanguard Growth ETF, and Walt Disney. The Motley Fool recommends Broadcom and Ge Vernova and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
2025-11-30 02:06 5mo ago
2025-11-29 20:00 5mo ago
Almonty Industries expanding U.S. tungsten mining stocknewsapi
ALM
Almonty Industries chairman and CEO Lewis Black discusses new tungsten mine in Montana amidst prices skyrocketing on ‘The Claman Countdown.'
2025-11-30 02:06 5mo ago
2025-11-29 20:05 5mo ago
Is This the Undiscussed Reason Buffett Just Bought Alphabet (Google) Stock? stocknewsapi
GOOG GOOGL
Apple and Alphabet just inked a big deal.

The investing community was abuzz with the news last week that Warren Buffett and his team at Berkshire Hathaway had bought only one new stock in the third quarter, and it was Alphabet (GOOG 0.05%) (GOOG 0.05%).

That was a significant departure from Buffett's classic stance of generally avoiding tech stocks. He does already own stakes in Apple (AAPL +0.47%) and Amazon, but one could argue that he bought them for other reasons. For example, one can argue that Apple is really a consumer goods company, since it sells devices. Amazon, meanwhile, has a massive retail business, and, in any case, Buffett has explicitly stated that it was one of his investing managers, Todd Combs and Ted Weschler, who made the call to buy it. However, he has repeatedly expressed his admiration for Jeff Bezos.

Alphabet, though, is more of a pure tech investment, and the team at Berkshire Hathaway bought it during a period when it was continuing to trim its stake in Apple. The conglomerate sold almost 41.8 million shares of Apple -- about 14.9% of its position as of the end of Q2. Based on its average price during the period, that would have amounted to sales of around $9.4 billion. Yet thanks to Apple's share price growth across that quarter, the value of Berkshire's stake in the iPhone maker still grew by about $3.2 billion.

Meanwhile, Berkshire loaded up on $4.3 billion worth of Alphabet stock.

However, all of this may be more of a signal of confidence in Apple than investors realize.

Image source: Getty Images.

Is Buffett down on Apple?
At the end of 2023, Berkshire Hathaway's stake in Apple represented a full 50% of the value of its equity portfolio. That's not a very diversified portfolio, which might be why the company has started to sell the stake off in increments. It's down to just over 21% of the portfolio today.

Buffett has said he would never close the Apple position, and he praises the tech company and its leader, Tim Cook, all the time. But one of the reasons everyone needs to periodically assess their portfolios -- even "set it and forget it" investors -- is that having too large a portion of your funds invested in one stock or a small handful of them can be risky. Consider that Apple stock has been trailing the market this year, even though it has recently surged a bit closer to parity with it. At several points in recent years, Apple was the most valuable company in the world, until Nvidia convincingly jumped to a solid lead this summer. Although I can't claim to know for certain why Buffett and his team were selling shares, that may have factored into the equation.

Another reason it may have looked like a good time to sell part of the position was the stock's valuation, which has become quite high. Apple trades at a P/E ratio of 37, even though it's growing quite slowly. That premium is likely due to the company's stability and reliability.

But considering that Apple stock is still the largest position in Berkshire's portfolio, I don't think Buffett is losing confidence in it. In fact, the investment in Alphabet may be another way he's voting for Apple.

Today's Change

(

0.47

%) $

1.30

Current Price

$

278.85

Investing in Alphabet is also investing in Apple's future
Just after Berkshire Hathaway submitted its latest 13F filing to the Securities and Exchange Commission (SEC), Bloomberg reported that Apple has agreed to pay Alphabet $1 billion annually to use its large language model (LLM), Gemini, to power its Siri voice assistant.

Breaking this down, Apple is going to pay for the use of the LLM in improving Siri's functionality. The market has been concerned that Apple is lagging the pack in AI, and this deal is meant to help Siri catch up to rival voice assistants while Apple works on its own LLMs. Apple's bespoke version of Gemini will run on private Apple servers, and its high-parameter complexity will help Siri's summarize and planner functions gather information and perform complex tasks.

Today's Change

(

-0.05

%) $

-0.15

Current Price

$

320.13

Don't give up on Apple
Apple stock has been gaining ground recently based on excellent iPhone sales. The iPhone is Apple's signature product, and it's the most popular smartphone in the U.S. The new iPhone 17 is also doing very well in China. It hasn't made sense to bet against Apple in the past, and it wouldn't make sense to expect that the company will sit back and let rivals get too far ahead of it in AI. The fact that Alphabet will be providing a key new service to Buffett's favorite portfolio holding may have contributed to Berkshire's decision to finally press the buy button on Alphabet stock.

That wouldn't be the only reason Buffett invested in Alphabet, though. He has long said he regrets not having invested in it earlier, as it has many of the features he loves in a company. This new partnership, though, makes his stock buy a vote of confidence in the futures of both Alphabet and Apple.
2025-11-30 01:06 5mo ago
2025-11-29 19:15 5mo ago
Is Coca-Cola Stock a Buy Right Now? stocknewsapi
KO
Coca-Cola won't deliver explosive returns, but its business model has overcome a range of challenges, from wars to inflation cycles.

Coca-Cola (KO +0.31%) rarely shows up on lists of high-growth stocks or disruptive innovators. However, it often appears on another list -- the one investors turn to when they want stability, dependable income, and a business model that performs well across economic cycles.

With the market seeking direction and investors weighing risks more carefully, Coca-Cola's defensive profile appears appealing again. The question is whether the stock is a buy today, especially for those thinking in 5- to 10-year horizons.

To answer that, we need to examine the company's strengths, its valuation, and the real headwinds that could impact performance over the next decade.

Image source: Getty Images.

Why Coca-Cola looks compelling right now
A business with rare durability
Coca-Cola thrives on a system built for consistency. The company produces concentrates, maintains brand leadership, and relies on bottlers to handle manufacturing and distribution. This asset-light model enables Coca-Cola to maintain high margins, generate strong free cash flow, and achieve the kind of earnings stability that investors value during uncertain times.

The structure has proven itself across multiple generations. It helped the company navigate inflation spikes, currency swings, and supply chain disruptions far better than many other consumer brands. For investors looking for a dependable long-term holding, Coca-Cola's durability stands out.

Shareholder returns remain a core part of the story
Coca-Cola's dividend stands at 2.8%, and the company has raised its payout for more than 60 consecutive years -- a rare record even among the best dividend payers. The business generates enough free cash flow to support further increases, share buybacks, and investments in its expanding product portfolio.

For long-term shareholders, these steady returns matter. They form a meaningful part of total returns, especially when top-line growth is modest.

Emerging markets provide the next decade of volume growth
Markets such as India, Africa, Southeast Asia, and parts of Latin America continue to offer rising consumption, growing populations, and improving cold-chain infrastructure. Over the next decade, these regions are expected to drive the majority of Coca-Cola's incremental volume growth.

This opportunity matters because emerging market strength can offset stagnation in developed markets, thereby maintaining the long-term growth story intact.

Today's Change

(

0.31

%) $

0.23

Current Price

$

73.11

Where investors should be cautious
Growth will remain modest
Even with emerging markets and new product categories, Coca-Cola's growth is unlikely to deviate significantly from its historical pattern. Revenue and earnings are likely to compound at a single-digit annual rate. That's stable but not fast. Investors seeking double-digit growth will not find it here.

Health and sugar regulation will continue to tighten
Governments in the U.S., Europe, and many emerging markets are imposing sugar taxes, warning labels, and advertising restrictions. These policies don't threaten Coca-Cola's existence, but they create structural headwinds that limit volume growth. The company must continue shifting toward zero sugar and functional beverages to offset this pressure.

Valuation is reasonable but not deeply discounted
At roughly 23 times earnings, Coca-Cola stock trades near the middle of its historical range. The stock isn't expensive for a durable business, but it's not a bargain either. For investors buying today, returns will likely track earnings growth plus dividends, not rapid multiple expansion.

So, is Coca-Cola a buy right now?
The best answer is that it depends.

Yes, if you're looking for stability, dividends, and a business that can withstand economic cycles. Coca-Cola remains one of the most reliable consumer brands in the world. The company should continue to raise dividends, protect margins, and grow steadily through emerging markets and premium pricing.

No, if you're seeking high growth or asymmetric upside. Coca-Cola is not a multibagger from here, at least not in the next few years. It won't compound at tech-like rates or reinvent its business every few years. It's a defensive compounder, not a high-octane grower.

In short, Coca-Cola remains a sensible long-term hold for investors who value consistency over excitement. If you want a portfolio anchor -- not a rocket ship -- Coca-Cola still fits that role well.
2025-11-30 01:06 5mo ago
2025-11-29 19:16 5mo ago
ROSEN, A LEADING LAW FIRM, Encourages StubHub Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - STUB stocknewsapi
STUB
November 29, 2025 7:16 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 29, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of StubHub Holdings, Inc. (NYSE: STUB) pursuant and/or traceable to the Registration Statement issued in connection with StubHub's September 2025 initial public offering (the "IPO"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 23, 2026.

SO WHAT: If you purchased StubHub common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the StubHub class action, go to https://rosenlegal.com/submit-form/?case_id=48412 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 23, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Registration Statement was materially false and misleading and omitted to state that: (1) StubHub was experiencing changes in the timing of payments to vendors; (2) those changes had a significant adverse impact on free cash flow, including trailing twelve months ("TTM") free cash flow; (3) as a result, StubHub's free cash flow reports were materially misleading, and that; (4) as a result of the foregoing, defendants' positive statements about StubHub's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the StubHub class action, go to https://rosenlegal.com/submit-form/?case_id=48412 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276060
2025-11-30 01:06 5mo ago
2025-11-29 19:35 5mo ago
Why Novo Nordisk Stock Just Hit a 4-Year Low stocknewsapi
NVO
Novo Nordisk's drug trial failure is the latest in a series of 2025 woes for the company.

The share price of Danish pharmaceutical giant Novo Nordisk (NVO +1.31%) hit a four-year low Monday, falling below $44 a share in early trading, a level the stock hasn't seen since July 2021.

What's driving the drugmaker's share price fall?

GLP-1 drugs become a catalyst
For several years now, Novo Nordisk has been a leader in the exploding market for GLP-1 drugs that can effectively treat type 2 diabetes and obesity. Sales of its two main drugs -- Ozempic for diabetes and Wegovy for weight loss -- made Novo Nordisk Europe's largest company by market capitalization, and a stock market darling.

Those two branded drugs are in fact the same, semaglutide. It works by lowering blood sugar, slowing digestion, and reducing appetite.

And the market for such drugs is exploding. The global GLP-1 market was valued at about $52 billion in 2024. That's expected to balloon to $187 billion by 2032, a compound annual growth rate of almost 17%. And that's a conservative estimate -- some projections of the market's growth are considerably higher.

Image source: Getty Images.

New uses for GLP-1 drugs
But GLP-1 drugs are so effective at treating diabetes and obesity that they're now being evaluated for a host of other conditions, including cardiovascular disease, chronic kidney disease, liver disease, sleep apnea, substance abuse disorders, and neurodegenerative disease, among others.

It's that last one -- neurodegenerative disease -- that pushed Novo Nordisk's stock lower this week. The company has been testing semaglutide's effectiveness in slowing the progression of early-stage symptomatic Alzheimer's disease. Tests even reached a third trial.

But things didn't work out. On Monday, the company issued a press release entitled: "Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression." The drug did no better in reducing the progression of the disease than a placebo. So Novo Nordisk is discontinuing trials.

To be fair, treating Alzheimer's with semaglutide was always a long shot. Novo Nordisk itself had called the idea a "lottery ticket."

A series of misfortunes has plagued Novo Nordisk
But this latest news just puts an exclamation point on the company's 2025 woes, which collectively have pushed the once-darling stock down 48% so far this year.

The company has been steadily losing market share to competitor Eli Lilly (LLY 2.67%) in the white-hot GLP-1 market. In fact, Lilly claimed its share of the market for GLP-1-based drugs climbed to 58% year over year in the third quarter. Lilly is the clear winner -- for the moment, at least -- in the GLP-1 drug contest. And as investors have woken up to this, they briefly pushed its market cap to $1 trillion last week.

While Lilly's share price has since receded a bit, its market cap is still about 5 times that of Novo Nordisk. Lilly's stock is up 42% this year, wildly outperforming not only Novo Nordisk, but also the broader market (the S&P 500 index is up 15.5% year to date).

Plus, in a desperate quest to find new GLP-1 drugs to bring to market, Novo Nordisk and rival Pfizer (PFE +0.12%) recently engaged in a bidding war for biotech start-up Metsera, a next-generation, clinical-stage biopharmaceutical company that's developing several obesity treatments.

Today's Change

(

1.31

%) $

0.64

Current Price

$

49.35

One of Metsera's drug candidates, MET-233i, can be taken less frequently than the Novo Nordisk and Eli Lilly drugs, and has proven highly effective -- it helped patients in one study to lose 8.4% of their body weight in 36 days.

But on Nov. 7, Metsera's board abruptly ended the bidding war by choosing Pfizer's latest bid, leaving Novo Nordisk out in the cold.

The battle is not yet over for the GLP-1 market
The race to win a significant share of the GLP-1 market -- and to find new uses for the drugs -- is far from over. That's in part because obesity is a chronic disease that can lead to or exacerbate many other health issues, from heart disease and high blood pressure to diabetes to sleep apnea -- and even some cancers.

Novo Nordisk performed well early in the battle for the GLP-1 market. It's now down, but probably not yet out.
2025-11-30 01:06 5mo ago
2025-11-29 20:00 5mo ago
Data Centers Are a ‘Gold Rush' for Construction Workers stocknewsapi
AAAU BAR DBP DGL GLD GLDM IAU OUNZ SGOL UGL
Surging demand for workers means six-figure pay and more perks.
2025-11-30 00:06 5mo ago
2025-11-29 16:40 5mo ago
Has Buffett's Recent Buy of POOL Stock Been Good for Investors? stocknewsapi
POOL
This recent addition to Buffett's portfolio has been underperforming. How has it done over the long term?

Legendary investor Warren Buffett has gotten plenty of criticism over the years. Much of it has stemmed from his decisions to hold on to slumping stocks in his Berkshire Hathaway (BRK.A +0.29%) (BRK.B +0.51%) portfolio if he believes in the long-term potential of their underlying businesses. This long-term buy-and-hold strategy has made him a multibillionaire and silenced most of his critics.

However, even Buffett admits that he's made some mistakes over the years. Could Berkshire's recent buy of pool equipment wholesaler Pool Corp. (POOL 0.27%) be a mistake? Here's how the stock has treated its investors who bought in before Buffett, and how it might treat investors today.

Image source: The Motley Fool.

1 year: How Pool stock has done for Buffett
Berkshire Hathaway first announced that it had bought shares of Pool about a year ago. Over the past year, though, the stock has been a big underperformer, with shares sliding from about $400 per share a year ago to the $300 per share range by April 2025, and to only about $245 a share today. That's a drop of about 33%, meaning that investors who bought in around the same time as Berkshire have lost roughly one-third of their investment.

That's bad, but things look even worse when you factor in that the S&P 500 has actually risen by about 14% over that time. This means that investing in Pool has underperformed the broader market by about 47 percentage points. Most analysts think the slumping housing market is to blame, as new pool installations occur when a house is built, and major repairs and renovations are likely to happen when a house is being prepared for sale.

But that's just the past year. How has Pool stock done over the longer term?

3 years and 5 years: Medium-term performance
Pool has actually done even worse over the medium term. Its three- and five-year performances are slightly better on an absolute basis, with shares of the stock only down about 26% since November 2022 and 25% since November 2020. But when we factor in the opportunity costs, the results look really bad.

Today's Change

(

-0.27

%) $

-0.67

Current Price

$

243.60

Because the S&P 500 has grown by nearly 75% over the last three years and nearly 100% over the last five years, the opportunity cost of taking a stake in Pool has been massive -- about 100 percentage points over three years and 125 percentage points over five. For investors who bought during the company's peak in late 2021, as lockdown-era pool installations skyrocketed during the pandemic's height, the performance is even worse.

Even the company's small dividend doesn't staunch much of the bleeding. Reinvesting your dividends would have curbed your five-year losses by only about 1.75%.

What's next for Pool
Although Pool's stock is currently in a slump, it's likely to recover once the real estate outlook changes. However, there's no guarantee when that will happen, so investors who take a stake in Pool may need to be very patient indeed.

Pool offers a good lesson, too, that even for buy-and-hold investors, there's no such thing as a "set it and forget it" stock. It's a good idea to monitor your investments at least once per quarter, to make sure you're on track to meet your investing goals.
2025-11-30 00:06 5mo ago
2025-11-29 16:50 5mo ago
How Has LULU Stock Done for Investors? stocknewsapi
LULU
LULU is the stock ticker for athletic apparel company Lululemon Athletica (LULU +1.24%). And Lululemon has done quite poorly for investors in 2025.

Investing $1,000 in Lululemon stock on Jan. 1 would have been a mistake. As of this writing, it's the fourth-worst performer in the S&P 500 this year, having lost 52% of its value. This means that the $1,000 investment is worth just $480 now, even though the S&P 500 is up 16%.

Admittedly, almost any stock has a bad year on occasion. So how have Lululemon's stock returns been over the last three to five years?

Image source: Getty Images.

Zooming out to see the big picture on Lululemon
Unfortunately for shareholders, zooming out doesn't help Lululemon's performance. Lululemon stock is down almost 50% over the last three years and down 49% over the last five years. Meanwhile, the S&P 500 is up 69% and 88% during these periods, respectively.

Lululemon's business has performed much better than one might think from looking at the stock performance. Over the last five years, the company's revenue has more than doubled, which is a remarkable achievement for any company. And its earnings per share (EPS) have more than tripled, which is exactly what investors should want to see.

Data by YCharts.

In short, Lululemon's business has performed well, whereas the stock price hasn't.

This is reflected in the valuation for Lululemon stock. Right now, it trades at just 11.5 times its earnings, which is its lowest valuation in more than a decade and its lowest valuation ever outside of the Great Recession.

Today's Change

(

1.24

%) $

2.25

Current Price

$

184.19

In other words, investors are expressing heightened pessimism about the future of this business.

What about the next five years?
Lululemon's fiscal 2024 ended on Feb. 2, 2025. During the fiscal year, sales in North America accounted for a whopping 75% of its total sales. But it's the North American markets that are experiencing slowing growth. Meanwhile, sales are booming internationally.

In its fiscal second quarter of 2025, Lululemon grew net revenue in international markets (outside North America) by 22%. That's a great growth rate that's mostly overlooked because it's still a small percentage of the overall business.

In short, even though sales are sluggish in its biggest markets, Lululemon has considerable room to grow internationally over the next five years. This revenue base is small now, but it could realistically double in size in the coming years. Therefore, investors may be overly pessimistic.

Given its strong profitability, its ongoing growth opportunities, and its currently cheap valuation, I believe it's likely that Lululemon will perform much better over the next five years than it did in the last five.
2025-11-30 00:06 5mo ago
2025-11-29 17:02 5mo ago
Constellation Brands Stock Sell-Off: Should You Buy the Dip? stocknewsapi
STZ
It's been a tough past couple of years for Constellation Brands (STZ +1.10%) shareholders. The stock's down more than 50% from its early 2024 peak, and seemingly still moving lower. The end of the COVID-19 pandemic's worst and the beginning of an inflation-riddled period is taking a double-barreled toll on alcohol consumption. Not only are people drinking less of it for health-minded reasons, but for cost-related reasons as well.

The sellers, however, have arguably overshot their target, ignoring how the company's foreseeable future looks much better than its recent past. This budding turnaround makes the pullback an attractive entry opportunity for patient investors.

Constellation Brands is on the defensive
You may know the company better than you think. Constellation is parent to popular beer brands Modelo and Corona, which account for the bulk of its revenue. It also owns a handful of smaller wine brands, like Kim Crawford and Ruffino, as well as spirits like High West whiskey and Mi Campo tequila.

The $23 billion company did $10.2 billion worth of business last fiscal year, up slightly from the previous year's top line.

Today's Change

(

1.10

%) $

1.49

Current Price

$

136.38

That would be the end of a respectable growth streak, though. Sales are down 10% through the six-month stretch ending in August. Gross profits and operating profits are similarly lower, mostly thanks to "a difficult socioeconomic environment that dampened consumer demand across the industry."

That's not an inaccurate explanation. The Beer Institute reports that through September, shipment volume is down 5%, jibing with data from the Brewers Association. Separately but simultaneously, a recent survey from Gallup confirms the business' worst fears -- a record-low 54% of American adults are now regular drinkers, with a majority of this crowd citing health concerns as their top reason for cutting back.

To this end, Constellation Brands' guidance for the full year ending in February suggests a 4% to 6% top-line dip, leading to a slightly bigger decline in operating income.

STZ Revenue (Quarterly) data by YCharts.

The bullish case
But things are about to change in a way the market isn't pricing in -- or even seeing -- yet. In simplest terms, think of 2025 as a reconfiguration year for Constellation Brands. It's rebuilding a better business for what should (hopefully) be a better business environment.

Chief among these changes so far is the decision made earlier this year to shed certain wine brands with lower price points. Although wine isn't a particularly big piece of the company's revenue, as CEO Bill Newlands explained of the move, "concentrating our wine and spirits portfolio in higher-growth segments remains an important element of our overall business strategy and complements our higher-end beer portfolio."

He's right. While overall alcohol consumption is down, higher-end alcohol consumption is up, even if only modestly. This bodes well for Constellation's breadwinning beer brands Modelo and Corona, neither of which are priced out of reach for most beer drinkers, but both of which are clearly priced above most baseline beers.

Image source: Getty Images.

Then there are the company's more operationally minded efforts. In Newlands' words, spoken at Barclays' recent consumer staples company conference, Constellation is "controlling the controllables." This includes plans to cull $200 million worth of unnecessary annual spending by the end of fiscal 2028. For perspective, the analyst community expects the company to earn $1.86 billion this year.

Perhaps the most compelling reason to step into this stock while it's down, however, is the cyclical swing that's not evident yet, but sure to be brewing. That's a rebound of the broad beer business driven by rekindled economic strength. If there's one thing veteran investors know, it's that everything ebbs and flows, including different categories of consumer goods. These same veteran investors also know the turnaround often takes shape with little to no warning.

In the meantime, newcomers will be plugging into this stock while its forward-looking dividend yield stands at just over 3%. That's not a bad way to start out a new trade.

More reward than risk
This is certainly no guarantee that Constellation Brands shares are ready to soar. There's no guarantee that they've even hit their ultimate low. There's risk here, to be sure.

With a forward-looking price-to-earnings ratio of less than 20 for a company that's usually profitable though, most of any risk has likely been wrung out. It may not be your highest-growth prospect, but it's certainly not your most dangerous.

More than anything, you're buying into one of the highest-quality companies in an industry with proven long-term staying power. Alcohol's current headwind isn't going to last forever. You'll want to dive in during the headwind when the stock's beaten up -- not after the recovery is well underway.

This might help. Although the stock's been a poor performer for a while, the analyst community isn't discouraged. They're actually becoming more bullish. Most of them are calling Constellation a buy, with a consensus price target of $169. That's 28% above the stock's present price, which isn't a bad way to start out a new trade.
2025-11-30 00:06 5mo ago
2025-11-29 17:03 5mo ago
Airbus orders software fix to thousands of planes due to solar radiation risk stocknewsapi
EADSF EADSY
Flights were delayed and cancelled globally after Airbus ordered fixes to 6,000 of its A320 series planes, according to The Guardian.

The company said it’s taking action because “analysis of a recent event involving an A320 Family aircraft has revealed that intense solar radiation may corrupt data critical to the functioning of flight controls.”

Citing industry sources, Reuters reports that the event in question was an October 30 JetBlue flight from Cancun, Mexico to Newark, New Jersey, in which the plane suddenly lost altitude and had to make an emergency landing in Tampa.

The Federal Aviation Administration has reportedly issued an emergency airworthiness directive calling for the affected planes to revert to earlier software before they can fly again. A smaller subset will need to have their hardware changed, Airbus said.

Topics
2025-11-30 00:06 5mo ago
2025-11-29 17:31 5mo ago
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLX stocknewsapi
TLX
November 29, 2025 5:31 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 29, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period"), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Telix securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Telix class action, go to https://rosenlegal.com/submit-form/?case_id=43778 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 9, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) defendants materially overstated the quality of Telix's supply chain and partners; and (3) as a result, defendants' statements about Telix's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Telix class action, go to https://rosenlegal.com/submit-form/?case_id=43778 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276057
2025-11-30 00:06 5mo ago
2025-11-29 17:32 5mo ago
Should You Buy Cameco While It's Below $90? stocknewsapi
CCJ
The uranium company has gone on a tear in recent years. Today, the stock is down 24% from its recent peak, which could be a buying opportunity for investors.

It's been quite an exciting ride for investors in Cameco (CCJ 0.34%), who have seen the stock rise 63% this year and more than 251% over the past three years. As the world once again embraces nuclear energy, Cameco is one uranium company that stands to benefit.

The U.S. government is making an effort to "unleash American energy." It's investing heavily in nuclear infrastructure and streamlining the approval process to meet the country's soaring energy demands.

Cameco's stock has recently pulled back from its 52-week high and is now 24% below that level, trading under $90. With nuclear energy having a revival, is the stock a smart buy at this price? Let's examine the company and its long-term opportunities to find out.

Soaring demand creates a need for more energy
Energy demand is soaring, driven by the explosion of power-hungry data centers running artificial intelligence (AI) algorithms. According to a Goldman Sachs report, data center power demand is expected to account for 8% of total U.S. demand by 2030, up from 3% just two years ago.

Not only will data centers drive energy growth, but demand across the board is expected to increase. Research from the Bank of America Institute projects that U.S. electricity demand will grow 2.5% annually, a rate five times faster than the previous decade, when demand grew 0.5% per year.

This surge in energy demand illustrates why the U.S. needs more infrastructure and why companies like Cameco stand to benefit.

The miner is well-positioned with its uranium assets
Cameco is one of the world's largest uranium producers, with assets in key uranium-producing regions in Canada and Kazakhstan. The company holds stakes in McArthur River (70% ownership) and Cigar Lake (55%), both of which are high-grade uranium mines in northern Canada. In the same area, it also owns an 83% stake in the Key Lake uranium mill, which processes ore to extract and concentrate uranium. In addition, it has a 40% interest in Joint Venture Inkai in Kazakhstan.

Today's Change

(

-0.34

%) $

-0.30

Current Price

$

88.51

Besides mines, Cameco holds a 49% stake in Westinghouse through a strategic partnership with Brookfield Renewable Partners. Westinghouse is an original equipment manufacturer of nuclear reactor technology and a global provider of products and services to commercial utilities and government agencies.

Recent news bodes well for the industry
Earlier this year, President Donald Trump signed executive orders to accelerate the deployment of nuclear power. Cameco, Brookfield Asset Management (Brookfield Renewable Partners' parent company), and Westinghouse Electric have partnered with the U.S. government to help in these efforts.

Image source: Getty Images.

As part of this partnership, they will build at least $80 billion in new reactors across the U.S. using Westinghouse nuclear reactor technology. The Westinghouse AP1000 reactor design is considered uniquely positioned to play a crucial role in the growing nuclear industry.

This partnership could pave the way for a major program of nuclear reactor building in the U.S. and Western-aligned countries. One Bank of America analyst raised his net asset value estimate for Cameco and applied a higher multiple, acknowledging the increasing growth potential from the miner's 49% interest in Westinghouse.

Cameco also benefited from reports in September that the Trump administration was recommending the U.S. increase its strategic uranium reserve to buffer against potential disruptions in Russian supplies.

Recent production cuts aren't a concern
In other news, Cameco announced a reduction in its 2025 production forecast. This is due to development delays and slower-than-anticipated ground freezing as the McArthur River mine transitions into new mining areas, which are expected to defer the extraction of projected amounts.

Production from its McArthur River/Key Lake operation is now anticipated to be between 14 million and 15 million pounds of U308 uranium, down from the previous forecast of 18 million pounds. Cameco's share of this is between 9.8 million and 10.5 million. However, strong performance at the Cigar Lake mine will help to partly offset up to 1 million pounds of the total shortfall.

Financial services firm Cantor Fitzgerald called the production guidance cut "immaterial," believing the shortfall is minor and will be recouped in 2026.

A play on the nuclear build-out
Cameco stands to benefit from the nuclear energy renaissance. The company holds key assets in high-grade uranium mines, while its investment in Westinghouse provides another avenue for growth.

One thing that may cause investors to balk at the stock is its valuation. It currently trades at 55 times this year's projected earnings, which is expensive for a mining stock. However, analysts project the company's earnings per share (EPS) will grow to $2.25 by 2028, representing 30% annual growth from 2025's projected EPS.

Although the stock is expensive, Cameco has a bright future, and more opportunities await it as the U.S. continues to build nuclear infrastructure. For these reasons, I think the recent dip is a good buying opportunity for investors.
2025-11-30 00:06 5mo ago
2025-11-29 17:35 5mo ago
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Avantor, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AVTR stocknewsapi
AVTR
November 29, 2025 5:35 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 29, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Avantor, Inc. (NYSE: AVTR) between March 5, 2024 and October 28, 2025, both dates inclusive (the "Class Period"), of the important December 29, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Avantor common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Avantor class action, go to https://rosenlegal.com/submit-form/?case_id=47303 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants misrepresented and/or failed to disclose that: (1) Avantor's competitive positioning was weaker than defendants had publicly represented; (2) Avantor was experiencing negative effects from increased competition; and (3) as a result, defendants' representations about Avantor's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Avantor class action, go to https://rosenlegal.com/submit-form/?case_id=47303 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276055
2025-11-30 00:06 5mo ago
2025-11-29 18:01 5mo ago
Upwork's CEO Sold Nearly $7 Million in Company Stock. Is This a Warning Sign for Shareholders? stocknewsapi
UPWK
As a leading online work marketplace, this platform reported significant insider selling amid a year of double-digit stock gains.

Hayden Brown, President & CEO of Upwork (UPWK +0.82%), disclosed the sale of 350,000 shares in multiple open-market transactions on November 25, 2025 and November 26, 2025; see the SEC Form 4 filing for details.

Transaction summaryMetricValueShares sold350,000Transaction value~$6.8 millionPost-transaction shares697,894Post-transaction value (direct ownership)~$13.7 millionTransaction value based on SEC Form 4 weighted average purchase price ($19.51); post-transaction value based on November 26, 2025 market close ($19.51).

Key questionsHow significant was the transaction relative to Hayden Brown's direct holdings?
The 350,000 shares sold represented 33.4% of Ms. Brown's direct holdings immediately prior to the transaction, a substantial reduction compared to the historical median sell trade of 30,672 shares (2.19% of holdings per trade in the past year).Did the transaction exhaust Ms. Brown's available direct ownership or leave a meaningful residual stake?
After the transaction, Ms. Brown retained 697,894 shares directly, valued at approximately $13.7 million as of November 26, 2025, which accounts for 0.53% of Upwork's outstanding shares based on the latest reported figures.How does the transaction compare to Ms. Brown's historical selling patterns?
Over the past year, Ms. Brown made 15 sell trades with a median size of 40,000 shares for sell-only events and 28,741 shares across all trade events, making this 350,000-share sale the largest single disposition in the observed period and well above both medians.Was there any notable movement in Upwork's stock price around the transaction dates?
Upwork shares closed at $19.58 on November 26, 2025, with the weighted average sale price at $19.51 per share; the stock posted a one-year total return of 16.3% as of the transaction date.Company overviewMetricValueMarket capitalization$2.58 millionRevenue (TTM)$780.86 millionNet income (TTM)$246.96 million1-year price change16.32%* 1-year price change calculated using November 26, 2025 as the reference date.

Company snapshotUpwork provides an online work marketplace connecting businesses with independent professionals and agencies across a wide range of categories, including sales, marketing, IT, and creative services.The company generates revenue primarily through service fees charged to clients and freelancers for facilitating talent sourcing, contracting, collaboration, and payment processing on its platform.Upwork targets enterprises, small and medium-sized businesses, and individual entrepreneurs seeking flexible, remote, and specialized talent globally.Upwork, Inc. operates at scale as a leading online staffing and employment services platform, leveraging technology to streamline remote talent engagement for businesses worldwide. The company’s strategic focus on digital marketplace efficiency and secure payment solutions positions it as a key enabler in the evolving flexible workforce landscape.

Upwork's broad talent pool and comprehensive platform functionalities offer a competitive edge in serving diverse client needs across industries.

Foolish takeCEO Hayden Brown's sale of 350,000 shares in Upwork is noteworthy because it's a significant portion of her holdings. The company's stock hit a 52-week high of $20.54 in September, and remained elevated at the time of her sale. This suggests Ms. Brown was taking advantage of this to capture some gains.

Hayden Brown continues to own nearly 700,000 Upwork shares, so her November disposition isn't necessarily a red flag for shareholders to sell. That said, the substantial size of her sale understandably raises concerns.

So far, Upwork is experiencing respectable performance in 2025. It reached record quarterly revenue of $201.7 million in the third quarter, representing a 4% year-over-year increase. Its Q3 net income rose 6% year over year to $29.3 million.

The company expects full-year 2025 revenue to range between $782 million and $787 million, which is an increase over 2024's $769.3 million. This is a positive sign, although not spectacular sales growth.

Upwork stock's price-to-earnings ratio of about 11 hovers near a high point for 2025, signifying shares are on the pricey side. This indicates now is a good time to sell, which may have contributed to Hayden Brown's large disposition. However, in terms of whether to buy, the earnings multiple signals now is not a good time to pick up shares.

GlossaryOpen-market transaction: The buying or selling of securities on a public exchange, not through private agreements.
SEC Form 4: A required filing disclosing insider trades by company officers, directors, or significant shareholders.
Weighted average purchase price: The average price paid per share, weighted by the number of shares in each transaction.
Direct ownership: Shares held personally and directly by an individual, not through trusts or indirect means.
Outstanding shares: The total number of a company's shares currently held by all shareholders.
Disposition: The act of selling or otherwise transferring ownership of an asset or security.
Total return: The investment's price change plus all dividends and distributions, assuming those payouts are reinvested.
Service fees: Charges collected by a platform for facilitating transactions or providing services to users.
Talent sourcing: The process of finding and recruiting skilled professionals for specific roles or projects.
Payment processing: Handling and transferring payments between parties, often through a secure online system.
TTM: The 12-month period ending with the most recent quarterly report.
2025-11-30 00:06 5mo ago
2025-11-29 18:03 5mo ago
The Smartest Technology ETF to Buy With $100 Right Now stocknewsapi
VGT
Here's how to invest in the latest tech trends without trying to pick winners on your own.

The technology sector is booming right now, largely due to the monumental growth of artificial intelligence (AI). But picking long-term tech winners is notoriously difficult, and it can be safer to spread your money out among many companies.

That's what makes buying a technology exchange-traded fund (ETF) a good idea. You'll be invested in a variety of leading tech players and benefit regardless of who dominates. You can also invest just $100, or even less, depending on which brokerage you use.

If this sounds appealing to you, here's why buying the Vanguard Information Technology ETF (VGT +0.71%) is a great place to put your money right now.

Image source: Getty Images.

Tech will likely dominate the market's returns for years to come
The Vanguard Information Technology fund spreads its investment across 300 small- and large-cap technology companies, tracking the MSCI US Investable Market Information Technology 25/50 Index. This provides investors with exposure to a range of top semiconductor and software companies, including Nvidia and Microsoft.

The fund currently has more than 51% of its holdings in semiconductor and software companies, with the remainder comprising tech hardware, application software, communications equipment, and other related industries. Not only is this significant diversification, but because the fund is invested in both large and small-cap companies, you won't miss out on owning rising disruptors in the industry.

It is also important to note that technology stocks have been a dominant force in the stock market's rise, essentially since the 1990s. The AI boom is the latest iteration of technology's influence on the market, and there's no end in sight for the influence of technology stocks.

The result has been very positive for investors who own the Vanguard Information Technology ETF. The fund has had an average annual return of 14.4% since its inception in 2004.

Of course, there's no guarantee it will continue at that pace. Still, it's an indicator of how well the fund can perform when technology companies are benefiting from long-term opportunities, such as the early days of the internet, mobile devices, and now AI.

The fund won't steal your returns
One thing to remember when choosing an investment fund is that all of them charge an expense ratio. This is a small fee that you pay annually to cover the costs of the investment firm managing the fund.

ETF expense ratios are often less expensive than mutual fund fees, so you're already ahead if you're considering an ETF. But you'll do even better by choosing a Vanguard ETF because its funds have some of the lowest expense ratios in the industry.

Today's Change

(

0.71

%) $

5.27

Current Price

$

752.20

The Vanguard Information Technology ETF is no exception, charging an expense ratio of just 0.09% -- significantly lower than the average fee of 0.94% for similar funds. That means if you have $10,000 invested in this fund, you'll only pay $9 in annual fees. 

With such low fees, you'll be able to keep more of the gains you earn over time, making your investment much more profitable than if you were to buy a more expensive fund with similar returns.

The same buy-and-hold rules for stocks apply to ETFs
It's important to remember that when buying an ETF, you should apply the same buy-and-hold strategy to owning it as you would any stock. Jumping in and out of funds when they rise and fall is a good way to diminish your potential returns.

Instead, consider buying the Vanguard Information Technology ETF and holding it for at least five years, ideally longer, and add to it when possible. Do that for years, and you'll be well on your way to building a strong portfolio.
2025-11-30 00:06 5mo ago
2025-11-29 18:03 5mo ago
South Korean e-commerce firm Coupang says 33.7 million customer accounts breached stocknewsapi
CPNG
South Korean e-commerce giant Coupang said personal information from its 33.7 million customer accounts was exposed via unauthorized data access.
2025-11-30 00:06 5mo ago
2025-11-29 18:33 5mo ago
Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%? stocknewsapi
MRK
The struggling pharmaceutical giant is showing signs of life.

Over the past 18 months, Merck (MRK +0.19%) shares have been mostly southbound as the drugmaker encountered several headwinds. Its vaccine business isn't performing as well as expected, resulting in lower revenue growth than anticipated. Furthermore, there are a growing number of mid- or late-stage clinical candidates that could challenge the dominance of Keytruda, its blockbuster cancer drug.

However, Merck has been working hard to navigate these headwinds. Recent developments have given the company's prospects -- and share price -- a boost. Let's find out what those are, and what they could mean for investors.

Merck records an important mid-stage win
In 2021, Merck acquired Acceleron Pharma, a smaller drugmaker, for $11.5 billion. The key asset from the transaction was sotatercept, which was, at the time, an investigational medicine for pulmonary hypertension (PH, a type of high blood pressure in the lungs).

Sotatercept has since earned approval, is marketed under the brand name Winrevair, and is indicated to treat a specific type of PH called pulmonary arterial hypertension (PAH), which happens when blood flow in the lungs is disrupted due to the narrowing of blood vessels. Winrevair is performing pretty well so far. The medicine was approved just last year and has generated $976 million through the first nine months of 2025.

Image source: Getty Images.

However, there could be even more in store for this compound. Merck recently announced that sotatercept successfully completed a phase 2 study in patients with combined post- and precapillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF). In simpler terms, that's when a patient develops two causes of PH at the same time (a subset of Group 2 PH, one of the more common forms of the disease).

This mid-stage win is a big deal for Merck. CpcPH due to HFpEF is classified as rare, but as the company pointed out, it's believed to be underdiagnosed. And right now, there are no treatments approved specifically for CpcPH. So Merck is targeting a specialist market, where it may not face much direct competition if sotatercept passes phase 3 studies and earns this label expansion.

Even with only around 100,000 patients -- which is well in the ballpark of "rare" -- the medicine could achieve significant success in this indication. It could add over $1 billion to the annual sales potential of sotatercept. That's why Merck's shares jumped on the news. The company might soon encounter competition, whether from biosimilars or otherwise, for Keytruda. But sotatercept's progress is giving the market confidence that it will be a key asset in helping Merck move beyond its current crown jewel.

There's even more good news
Several other developments bode well for Merck's prospects. Let's consider two.

First, the company recently announced that it would acquire Cidara Therapeutics (CDTX +0.06%) , a mid-cap biotech company, for approximately $9.2 billion in cash. Merck will get access to CD388, a potential therapy that could disrupt the influenza market. Current flu vaccines have significant drawbacks, including low or waning efficacy as the season progresses. They can also be less effective in some of the people who need them the most: the elderly and the immunocompromised.

CD388 seeks to address all these shortcomings. The medicine has performed well in phase 2 studies, and it could become an important addition to Merck's portfolio.

Today's Change

(

0.19

%) $

0.20

Current Price

$

104.83

Second, Merck is inching closer to another brand-new launch. The company's combination of doravirine and islatravir is being studied for treating HIV and is awaiting approval from the U.S. Food and Drug Administration, which could come down sometime early next year. It could be yet another product that will help Merck's post-Keytruda plans.

It's also worth pointing out that Merck has received approval for a subcutaneous version of Keytruda. Though lacking all the original version's indications, this new formulation won't face a patent cliff anytime soon. As Merck combines subcutaneous Keytruda with newer products like Winrevair, its potential HIV treatment, and Capvaxive -- a pneumonia vaccine that earned approval last year and generated $244 million in sales in the third quarter -- it should be able to get past the challenges to its core franchise.

Is the stock a buy?
The drugmaker may face more challenging days ahead as it navigates current issues with its vaccine business. However, it's showing why it has performed well for a very long time. Merck's deep pipeline and ability to identify attractive opportunities should allow it to perform well over the long run, despite the obstacles it faces.

Finally, Merck is a terrific dividend stock that has increased its payouts by 84.7% over the past decade and currently offers a forward yield of 3.5%. It may not be a stock to buy for explosive growth, but it is an excellent, reliable blue chip income stock to add to your portfolio.
2025-11-29 23:06 5mo ago
2025-11-29 14:23 5mo ago
Kalshi Traders Price Bearish Odds on $100K Bitcoin Rebound in 2025 cryptonews
BTC
Key NotesBitcoin price rebounded 17% this week but failed to break above the $95,000 resistance despite renewed ETF inflows.Prediction markets turned bearish after Kalshi’s market-manipulation lawsuit, with traders cutting odds of Bitcoin price retaking $100,000 before the end of 2025.BlackRock’s $117 million outflow and muted whale activity, including Strategy’s pause in weekly purchases, signal weakening bullish conviction.
Bitcoin price rebounded 17%, moving from lows near $82,000 on November 21 to graze the $93,000 level on November 28. Bitcoin ETFs recorded a combined $221 million in net inflows between Nov. 25 and Nov. 28. Still, despite closing Friday with a modest $74 million net-positive session, BTC failed to advance beyond the key $95,000 resistance.

Blackrock’s $117 million outflows of Friday stand out despite $74 million net inflows on Friday, Nov 28 | Source: FarsideInvestors

BlackRock’s heavy outflow of $117 million stood out. As the world’s largest asset manager, its positioning often sets the tone for other institutional investors globally.

Strategy (MSTR) Bitcoin purchase history Aug 11 to Nov 17, 2025 | Source: Bitbo.io

Further underscoring the cautious stance among Bitcoin whales, Strategy Inc. made no purchases last week, ending a 14-week run that began in August. According to Bitbo data, the Michael Saylor-led firm confirmed its last buy on Nov. 17, when it acquired 8,178 BTC for $836 million, lifting total holdings to 649,870 BTC.

Bitcoin’s weak momentum is also reflected in the prediction markets, where Kalshi now faces a major lawsuit over market manipulation and accusations of betting against its own users. Intraday Kalshi order books on Nov. 29 showed traders pricing lower odds of Bitcoin reclaiming $100,000 before the end of 2025, with markets increasingly leaning towards a close below $80,000.

Kalshi odds on Bitcoin price rebounding to $100,000 in 2025 drops 11% on Nov 29 | Kalshi

Odds on Bitcoin hitting $100,000 dropped 11% while odds on a $110,000 breakout also sank 7% to hit 45% at press time. Meanwhile, the odds of the Bitcoin price closing 2025 below the $80,000 mark rose 8% to hit 36%.

Bitcoin Price Forecast: Can Bulls Force a Break Above $95,000 Toward $100,000?
Bitcoin is attempting to rebuild structure after its sharp recovery from the $82,705 SAR cluster. As seen on the BTCUSD daily chart, Bitcoin price is now pinned under at $92,971, with the Keltner Channel mid-band forming a short-term compression that often precedes a directional breakout.

Momentum signals are improving but not yet confirmed. The MACD line has crossed into positive territory for the first time since early November, indicating early bullish momentum. The Woodies CCI also reclaimed the 0-line, with sequential higher lows, indicating renewed buyer participation as traders attempted to buy the dip.

Bitcoin (BTC) Technical Price Analysis | Source: TradingView

A decisive daily close above $95,000, aligned with the upper Keltner boundary, would re-establish bullish dominance and reopen the path toward $100,000, invalidating the current bearish prediction-market bias.

However, BTC risks another wave of rapid liquidation if the Bitcoin price fails to hold the $90,000 support over the weekend. Consecutive daily closes below $89,500 could weaken bullish momentum and trigger a correction toward $85,880, near the lower Keltner boundary.

Disclaimer: Coinspeaker is committed to providing unbiased and transparent reporting. This article aims to deliver accurate and timely information but should not be taken as financial or investment advice. Since market conditions can change rapidly, we encourage you to verify information on your own and consult with a professional before making any decisions based on this content.

Bitcoin News, Cryptocurrency News, News

Ibrahim Ajibade is a seasoned research analyst with a background in supporting various Web3 startups and financial organizations. He earned his undergraduate degree in Economics and is currently studying for a Master’s in Blockchain and Distributed Ledger Technologies at the University of Malta.

Ibrahim Ajibade on LinkedIn
2025-11-29 23:06 5mo ago
2025-11-29 14:32 5mo ago
Ethereum Technical Signals Point to $3,400 Test Ahead of FUSAKA Upgrade cryptonews
ETH
TLDR:

Ethereum price is coiling tightly, with RSI breakout signaling possible near-term movement.
RSI movements often lead Ethereum price, pointing to a potential $3,400 test.
FUSAKA upgrade scheduled for Dec 3, 2025, may influence market trends.
Historical Pectra upgrade showed 55% gain in 35 days and 168% in 109 days.

Ethereum is showing early technical signals ahead of the FUSAKA upgrade. 

The cryptocurrency is trading in a tight range, indicating low volatility. The Relative Strength Index (RSI) has already broken out. Price action is currently lagging behind momentum indicators.

The RSI breakout suggests potential movement in the near term. Analysts are noting that Ethereum may test higher levels. Technical indicators are being closely monitored. Traders are observing the coiling price pattern for signs of a breakout.

Ethereum’s price is coiling tightly, suggesting a period of consolidation. According to Merlijn The Trader, “Price is coiling tight. RSI already broke out. Moves like this don’t stay quiet for long.” RSI movements often precede price changes. Momentum indicators are signaling possible upcoming activity.

EARLY SIGNALS FROM ETHEREUM?

Price is coiling tight.
RSI already broke out.
Moves like this don’t stay quiet for long.

Price lags. RSI leads.
If Ethereum follows, $3.4K is the next test.

Momentum is shifting. Eyes on $ETH. pic.twitter.com/YFdz5eM3xm

— Merlijn The Trader (@MerlijnTrader) November 29, 2025

The breakout in RSI points to potential price tests. Ethereum’s price tends to lag behind RSI movements. Observers are identifying $3,400 as a possible next level if momentum continues. Technical setups are being closely tracked.

Merlijn notes that momentum is shifting, which could influence near-term price action. RSI is considered a leading indicator in technical analysis. Traders are watching consolidation and breakout patterns. Indicators provide signals ahead of price changes.

FUSAKA Upgrade Could Influence ETH Price Action
The FUSAKA upgrade is scheduled for December 3, 2025. Crypto Patel highlighted that the previous Pectra upgrade on May 7, 2025, triggered notable gains for Ethereum. Data shows a 55% increase within 35 days and 168% in 109 days post-upgrade. Historical patterns are being analyzed for potential trends.

$ETH Could Skyrocket to $7.8K After FUSAKA Upgrade – History Shows

The last Ethereum Pectra Upgrade on 7 May 2025 triggered a massive move:
✅ +55% in 35 days
✅ +168% in 109 days

What’s next?
The FUSAKA Upgrade is scheduled for 3 December 2025. If history repeats:

👉 Target… pic.twitter.com/ojZXLQSYWZ

— Crypto Patel (@CryptoPatel) November 29, 2025

Using the Pectra fractal as a reference, post-FUSAKA targets are $4,500 by January 7, 2026, and $7,800 by March 22, 2026. These projections are based on prior upgrade movements. Traders are observing these levels for reference. The FUSAKA upgrade may influence market behavior in the near term.

Crypto Patel advises that market reactions can vary despite historical trends. Observers continue to track Ethereum’s price and technical indicators. The FUSAKA upgrade is a focal point for upcoming activity. Market data is being analyzed in real time.

Ethereum is showing technical signals alongside an upcoming network upgrade. Price may test higher levels if current momentum continues. 
2025-11-29 23:06 5mo ago
2025-11-29 14:46 5mo ago
Ethereum's November Trading Frenzy: Spot Volume Hits $375B as ETFs Add $35B Punch cryptonews
ETH
ETH trading volumes surged from mid-year acceleration to a $599 billion peak.

The trading activity of Ethereum (ETH) has remained high throughout 2025. Interestingly, CryptoQuant data now reveals that spot trading volume across exchanges reached $375 billion in November.

Meanwhile, exchange-traded fund (ETF) volume climbed to nearly $35 billion.

Institutional Money Pours In
According to the analysis, Ethereum began the year with significant volatility in monthly trading activity, with total volume fluctuating between roughly $280 billion and $380 billion before accelerating sharply in the middle of the year.

That surge eventually led to a peak of more than $599 billion in August, and marked the highest monthly trading volume recorded during the period. Following this spike, trading activity eased but stayed comparatively strong, and ended November at around $375 billion, a level that indicates continued market participation despite ongoing price pressures.

CryptoQuant found that Binance remained the dominant venue for Ethereum trading, and recorded approximately $198 billion in spot trading volume during November alone. This figure underscores Binance’s central role in real-time liquidity flows and its position as the leading platform for both institutional and retail traders executing high-volume transactions.

Data also shows that institutional interest played a meaningful role through regulated investment vehicles, with Ethereum spot ETFs registering about $35 billion in trading volume for the month. Such a level of ETF activity points to continued engagement from traditional market participants and adds an additional layer of “organized liquidity” to overall Ethereum market flows during the period.

Currently, Ethereum is seeing renewed confidence from large investors as whale activity increasingly leans toward long positions, according to Alphractal’s Whale vs Retail Delta metric. On the price front, ETH has climbed above $3,000. Despite remaining around 24% lower over the month, the asset’s recovery coincided with aggressive accumulation from major holders.

You may also like:

How Undervalued Is Ethereum Really, and What’s ETH’s True Price Today?

Whales Are Leaning Into Ethereum (ETH) and Cardano (ADA): Retail Is Lagging Behind

Ethereum’s Vitalik Buterin Drops 256 ETH to Boost Next-Gen Encrypted Messaging

As recently reported by CryptoPotato, wallets holding 10,000-100,000 ETH now control a record level of over 21 million ETH, while entities with over 100,000 ETH have expanded their balance to around 4.3 million ETH.

ETH Near Neutral Zone
Further analysis reveals that Ethereum is trading near fair-value territory, as important on-chain indicators point to a sensitive phase in the market. Ethereum’s Realized Price stands at $2,315 and an MVRV ratio of 1.27. This places the asset in a neutral zone where the market price sits just 27% above the Realized Price, which shows neither overbought nor oversold conditions.

Binance-specific data reflects an even sharper shift, as Ethereum’s MVRV ratio on the exchange hovers near 0.999, just below the historically important threshold of 1.0. A reading under 1 means that market capitalization is aligning with the Realized Price, pushing most investors into a “no-profit, no-loss” position. This zone has historically coincided with early market bottoms or extended periods of price weakness.

On the other hand, long-term MVRV readings above 3 typically correspond with overbought phases, while values below 1 indicate market troughs characterized by unrealized losses. The current ratio of 1.27 points to a balanced market structure with no strong signals of extreme valuation.

Tags:
2025-11-29 23:06 5mo ago
2025-11-29 14:50 5mo ago
Arthur Hayes Predicts Collapse of Most Layer 1 Tokens Outside Ethereum and Solana cryptonews
ETH SOL
Arthur Hayes, co-founder of crypto derivatives exchange BitMEX, has warned that most Layer 1 blockchain tokens outside Ethereum and Solana are unlikely to survive long-term. In an interview with Altcoin Daily, he argued that many newly launched networks, despite attracting early investor attention, lack sustainable fundamentals and carry inflated valuations. Hayes emphasized that initial hype often creates short-term price gains but does not guarantee enduring success for these projects.

Monad and the Risks of High-Valuation L1sHayes specifically highlighted Monad, a recently launched L1 backed by Coinbase Ventures. At the time of his statement, MON token had risen 45% since its ICO, reaching roughly $0.037 with a market capitalization near $398 million. 

Despite these gains, Hayes expects a dramatic decline, citing the coin’s high fully diluted valuation and low circulating supply. He noted that many new L1s follow a pattern of early surges followed by sharp corrections, driven by initial investor optimism rather than fundamental value.

According to Hayes, new L1 projects often attract attention because investors hope to discover the next Ethereum. Early pumps create excitement, but most tokens fail to maintain momentum once hype fades. 

Venture capital support may temporarily prop up prices, but Hayes warned that this does not guarantee long-term success. Consequently, he believes most L1 tokens outside Ethereum and Solana are destined for collapse.

Ethereum and Solana: The Standout NetworksDespite the challenges facing newer L1s, Hayes identifies Ethereum and Solana as exceptions. He sees Ethereum as the foundation for institutional blockchain adoption. 

Large banks and organizations now prefer public networks over private chains due to security and utility advantages. Layer 2 solutions like Arbitrum and Optimism will help Ethereum scale while maintaining privacy, positioning it for sustained growth.

Solana, according to Hayes, remains the second-largest L1, benefiting previously from meme coin activity. However, he acknowledges that meme-driven growth has slowed. 

Solana will need a new catalyst to maintain user engagement and price momentum. While Hayes remains skeptical that it will surpass Ethereum, he believes the network will continue to play a significant role in the blockchain ecosystem.

Hayes’ Magnificent FiveIn addition to Ethereum and Solana, Hayes named Bitcoin, Zcash, and Ethena as his top cryptocurrency picks. These networks combine adoption, security, and practical utility, which he considers critical for long-term success. By contrast, most other L1 tokens face a high risk of decline as early enthusiasm fades.
2025-11-29 23:06 5mo ago
2025-11-29 15:05 5mo ago
UK's FCA Launches Stablecoin Regulatory Sandbox Amid Global Alliance Push cryptonews
SAND
// News

Reading time: 2 min

Published: Nov 29, 2025 at 20:05

Two distinct but related developments on November 28th underscored the rapid push for compliant, global stablecoin infrastructure—a foundational component for integrating crypto with traditional finance.

UK regulatory sandbox for stablecoins

The Financial Conduct Authority (FCA) in the United Kingdom announced that it is adding a stablecoin-specific cohort to its Regulatory Sandbox.

This program invites institutions ready to issue a stablecoin under the upcoming UK regulatory regime to apply for testing in a controlled environment. The goal is to shape the FCA's future policies and rules by gathering real-world data and insights from companies operating within the market.

The sandbox opens the door for regulated entities to test stablecoin solutions with consumers and utilize proprietary data, while receiving guidance from the FCA's Innovation Case Officers. This structured approach provides the regulatory certainty required by banks and major fintechs to invest heavily in tokenized money. This signals the UK's commitment to implementing a MiCA-like framework for stablecoins, focusing on stability and consumer protection.

Korean Won Stablecoin Alliance (GAKS)

Simultaneously, major Korean gaming company WEMADE, parent of the WEMIX blockchain ecosystem, announced the formation of the Global Alliance for Korean Won (KRW) Stablecoin (GAKS).

The alliance brings together global compliance leaders Chainalysis and CertiK, alongside fintech remittance company SentBe.

This partnership aims to build a KRW-backed stablecoin infrastructure that prioritizes security, regulatory compliance, and global scalability for cross-border remittances. By leveraging Chainalysis for Web3 threat detection and CertiK for security audits, WEMADE is ensuring that its StableNet infrastructure meets international regulatory standards.

This initiative is a response to the rapid advancement of stablecoin infrastructure and regulatory clarity in South Korea, positioning the nation to become a major player in the global stablecoin market, moving the digital asset beyond simple gaming ecosystems into real-world financial applications.

These two developments on opposite ends of the globe confirm that regulatory compliance and institutional-grade security are the current priority for the multi-trillion-dollar stablecoin sector.
2025-11-29 23:06 5mo ago
2025-11-29 15:10 5mo ago
1.75M Hyperliquid tokens unlocked today, but was the price impacted? cryptonews
HYPE
2 hours ago

The Hyperliquid development team provided clarity on Saturday's token unlock in response to community fears of increased selling pressure.

The team behind the Hyperliquid decentralized exchange (DEX) disclosed a 1.75 million HYPE token unlock for its developers and core contributors on Saturday, valued at over $60.4 million at the time of this writing.

Saturday’s token unlock was previously announced and is part of HYPE’s vesting schedule, according to pseudonymous Hyperliquid developer iliensinc, who celebrated the first anniversary of Hyperliquid’s historic airdrop and token generation event. He said:

“For perspective, about 270 million tokens were fully unlocked on Nov 29, 2024, in the largest airdrop in history, measured in today's market value at about $9.5 billion. There are no investor unlocks, as Hyperliquid never raised any external capital.” Source: iliensincThe unlock sparked fear about potential selling pressure that could impact HYPE’s market price, which declined by about 4.6% at the time of this writing.

Hyperliquid’s airdrop and token generation event was considered a landmark debut in the crypto industry that changed product launches, by touting a community-focused model, rewarding early adopters, developers, and users, as opposed to venture capitalists.  

Hyperliquid’s token unlocks are already priced in“Even if the team pinky swears to not sell, there is nothing holding them to that,” founder of the BitMEX crypto exchange and market analyst Arthur Hayes said.

HYPE token holders must expect a non-zero chance of daily selling pressure, which has already been priced in by the market, reflected in HYPE’s decline since September, Hayes added.

The price of HYPE has declined by about 42% from its all-time high of about $59.40, reached in September, and is trading well below its 200-day moving average, a critical support level.

HYPE’s price action shows a steady uptrend, culminating in an all-time high in September, followed by a decline. Source: TradingViewHYPE started falling on September 19, before the historic market crash in October that wiped away up to 95% in value from certain altcoins.

The token fell by about 54% in a single day during the October 10 market crash but rebounded to the $40 level within two days of the crash.

Analysts and crypto industry executives have praised Hyperliquid for its revenue generation and the platform’s ability to handle $330 billion in monthly trading volume with a small development team.

Magazine: Astrology could make you a better crypto trader: It has been foretold
2025-11-29 23:06 5mo ago
2025-11-29 15:17 5mo ago
Ethereum Trading Surges with $410 Billion in Combined Volumes for November cryptonews
ETH
Ethereum, one of the leading cryptocurrencies, experienced a robust trading environment in November 2025, as new data points to a substantial combined trading volume of $410 billion. This figure stems from both spot market activities, which alone accounted for $375 billion, and exchange-traded fund (ETF) trading, which contributed nearly $35 billion.
2025-11-29 23:06 5mo ago
2025-11-29 15:30 5mo ago
What's Going On Behind The Scenes With XRP? Expert Answers cryptonews
XRP
Conversations around XRP have grown louder in recent weeks as the cryptocurrency continues to trade around the $2.2 region while new Spot XRP ETFs continue to attract inflows across multiple issuers. 

One voice in the community has attempted to explain why the market is unusually calm despite rising institutional demand. An XRP enthusiast known as Pumpius shared a detailed thread on X that breaks down the mechanics behind the new ETFs and why the real impact may still be ahead. His argument is that the current XRP price action does not yet reflect what is going on behind the scenes.

Why ETF Rules Create A Special Market Dynamic
Pumpius explained that the foundation of the entire setup is in one legal detail with fund managers. ETF fund managers are restricted from purchasing XRP directly from Ripple or from the escrow accounts that hold large reserves of the token. Every ETF must source XRP through open-market purchases, without private deals or wholesale arrangements.

The absence of direct acquisition forces institutional buyers into the same liquidity pool as retail and whales. With the new launch of XRP ETFs, and as demand continues to rise, the circulating supply is now the battleground, and this mechanical pressure is already visible in recent weeks as XRP trading volumes climbed while exchange supply began trending downward. 

According to market trackers, XRP supply on major exchanges has declined steadily since the approval of the first Spot XRP ETFs, showing that the stress on available liquidity is not theoretical but active. Particularly, data from CryptoQuant shows that Binance’s XRP reserves are now at their lowest point in months, having dropped to 2.7 billion tokens this week.

XRPUSD currently trading at $2.18. Chart: TradingView
Incoming Supply Squeeze For XRP
Another part of the explanation focuses on Ripple’s behavior regarding escrow releases. Although one billion XRP is unlocked each month, Ripple has repeatedly returned about 700 million to 800 million of these unlocked  tokens back into escrow. 

Ripple releases only what it considers necessary to maintain healthy liquidity in the ecosystem, and the company has avoided significant selling pressure since the ETF approvals.

According to Pumpius, this means the ecosystem is operating in a controlled balance where ETF issuers are absorbing a growing share of the circulating float, while Ripple keeps escrow output extremely conservative. 

The result is a slow tightening of supply that’s happening behind the scenes and may not yet be visible in price action but can eventually cause what he called a structural supply shock. When this happens, XRP will not move slowly, but it will break price levels with impact.

Still speaking of what is happening behind the scenes, Ripple has been advancing several developments that could strengthen XRP’s long-term position. A recent example is Abu Dhabi’s financial regulator formally recognizing RLUSD as a fiat-referenced token.

Featured image from Unsplash, chart from TradingView
2025-11-29 23:06 5mo ago
2025-11-29 15:40 5mo ago
UK's Record Bitcoin Seizure Surge Global Scrutiny Over Crypto Crime and Missing Funds cryptonews
BTC
The United Kingdom has entered the global spotlight after concluding the largest cryptocurrency seizure in its history, uncovering a money laundering operation involving nearly 195,000 Bitcoin. At the center of the case is Chinese national Zhimin Qian, whose criminal network moved staggering amounts of digital wealth across borders to hide illicit financial activities.